

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Iterative delivery of an implementation support package to increase and sustain the routine provision of antenatal care addressing alcohol consumption during pregnancy: study protocol for a stepped-wedge cluster trial.

| | |
|-------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2022-063486 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 04-Apr-2022 |
| Complete List of Authors: | <p>Doherty, Emma; The University of Newcastle College of Health Medicine and Wellbeing, School of Medicine and Public Health; Hunter New England Local Health District, Population Health</p> <p>Wiggers, John; The University of Newcastle College of Health Medicine and Wellbeing, School of Medicine and Public Health; Hunter New England Local Health District, Population Health</p> <p>Nathan, Nicole; The University of Newcastle College of Health Medicine and Wellbeing, School of Medicine and Public Health; Hunter New England Local Health District, Population Health</p> <p>Hall, Alix; The University of Newcastle College of Health Medicine and Wellbeing, School of Medicine and Public Health; Hunter New England Local Health District, Population Health</p> <p>Wolfenden, Luke; The University of Newcastle College of Health Medicine and Wellbeing, School of Medicine and Public Health; Hunter New England Local Health District, Population Health</p> <p>Tully, Belinda; Hunter New England Local Health District, Population Health</p> <p>Elliott, Elizabeth; The University of Sydney, Faculty of Medicine and Health and Discipline of Child and Adolescent Health; Sydney Children's Hospitals Network Randwick, Kids Research Institute</p> <p>Attia, John; The University of Newcastle Hunter Medical Research Institute; The University of Newcastle College of Health Medicine and Wellbeing, School of Medicine and Public Health</p> <p>Dunlop, Adrian; Hunter New England Local Health District, Drug and Alcohol Clinical Services Research</p> <p>Symonds, Ian; The University of Adelaide, Adelaide Medical School</p> <p>Tsang, Tracey; The University of Sydney, Faculty of Medicine and Health and Discipline of Child and Adolescent Health; Sydney Children's Hospitals Network Randwick, Kids Research Institute</p> <p>Reeves, Penny; The University of Newcastle Hunter Medical Research Institute, Health Research Economics</p> <p>McFadyen, Tameka; The University of Newcastle College of Health Medicine and Wellbeing, Thurru Indigenous Health Unit; Hunter New England Local Health District, Population Health</p> <p>Wynne, Olivia; The University of Newcastle College of Health Medicine and Wellbeing, School of Medicine and Public Health; Hunter New England Local Health District, Population Health</p> <p>Kingsland, Melanie; The University of Newcastle College of Health</p> |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

| | |
|-----------|---|
| | Medicine and Wellbeing, School of Medicine and Public Health; Hunter New England Local Health District, Population Health |
| Keywords: | Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Organisational development < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH, OBSTETRICS |
| | |



BMJ Open: first published as 10.1136/bmjopen-2022-063486 on 26 July 2022. Downloaded from <http://bmjopen.bmj.com/> on April 7, 2024 by guest. Protected by copyright.

1 **Title:** Iterative delivery of an implementation support package to increase and sustain the
2 routine provision of antenatal care addressing alcohol consumption during pregnancy: study
3 protocol for a stepped-wedge cluster trial.
4

5 **Author names:** Emma Doherty^{a,b,c}, John Wiggers^{a,b,c}, Nicole Nathan^{a,b,c}, Alix Hall^{a,b,c}, Luke
6 Wolfenden^{a,b,c}, Belinda Tully^a, Elizabeth J Elliott^{d,e}, John Attia^{b,c}, Adrian Dunlop^{b,f}, Ian
7 Symonds^g, Tracey W Tsang^{d,e}, Penny Reeves^c, Tameka McFadyen^{a,b,c}, Olivia Wynne^{a,b,c},
8 Melanie Kingsland^{a,b,c}.

9
10 ^a Population Health, Hunter New England Local Health District, Wallsend, New South Wales,
11 2287, Australia

12 ^b School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The
13 University of Newcastle, Callaghan, New South Wales, Australia

14 ^c Hunter Medical Research Institute, New Lambton Heights, New South Wales, 2305, Australia

15 ^d Faculty of Medicine and Health and Discipline of Child and Adolescent Health, The
16 University of Sydney, New South Wales, 2006, Australia

17 ^e Sydney Children's Hospital Network, Kids' Research Institute, Westmead, New South Wales,
18 2145, Australia

19 ^f Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle,
20 New South Wales, 2302, Australia

21 ^g Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, 5005,
22 Australia

23
24 **Corresponding author**

25 Emma Doherty

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Mail: co/ Hunter New England Population Health

2 Locked Bag 10, Wallsend NSW 2287, Australia

3 Email: emma.doherty@health.nsw.gov.au

For peer review only

1 ABSTRACT

2 **Introduction:** Antenatal care addressing alcohol consumption during pregnancy is not
3 routinely delivered in maternity services. Although a number of implementation trials have
4 reported significant increases in such care, the majority of women still did not receive all
5 recommended care elements, and improvements dissipated over time. This study aims to assess
6 the effectiveness of an iteratively developed and delivered implementation support package in:
7 i) increasing the proportion of pregnant women who receive antenatal care addressing alcohol
8 consumption; and ii) sustaining the rate of care over time.

9 **Methods and analysis:** A stepped-wedge cluster trial will be conducted as a second phase of
10 a previous trial. All public maternity services within three sectors of a local health district in
11 Australia will receive an implementation support package that was developed based on an
12 assessment of outcomes and learnings following the initial trial. The package will consist of
13 evidence-based strategies to support increases in care provision (remind clinicians; facilitation;
14 conduct educational meetings) and sustainment (develop a formal implementation blueprint;
15 purposely re-examine the implementation; conduct ongoing training). Measurement of
16 outcomes will occur via surveys with women who attend antenatal appointments each week.
17 Primary outcomes will be the proportion of women who report being asked about alcohol
18 consumption at subsequent antenatal appointments; and receiving complete care (advice and
19 referral) relative to alcohol risk at initial and subsequent antenatal appointments. Economic and
20 process evaluation measures will also be reported.

21 **Ethics and dissemination:** Ethical approval was obtained through the Hunter New England
22 (16/11/16/4.07, 16/10/19/5.15) and University of Newcastle Human Research Ethics
23 Committees (H-2017-0032, H-2016-0422) and the Aboriginal Health and Medical Research
24 Council (1236/16). Trial findings will be disseminated to health service decision makers to
25 inform the feasibility of conducting additional cycles to further improve antenatal care

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 addressing alcohol consumption as well as at scientific conferences and in peer-reviewed
2 journals.

3 Trial Registration: Australian and New Zealand Clinical Trials Registry,
4 ACTRN12622000295741 (16/02/2022)
5 <https://www.anzctr.org.au/ACTRN12622000295741.aspx>

6 **Keywords:** quality in healthcare, organisational development, protocols and guidelines, public
7 health, obstetrics

For peer review only

1 ARTICLE SUMMARY

2 Strengths and limitations of this study

- 3 • This will be the first controlled trial to evaluate the effectiveness of an iteratively
4 developed and delivered implementation support package in increasing and sustaining
5 the routine provision of antenatal care addressing alcohol consumption during
6 pregnancy.
- 7 • The implementation support package was developed based on an assessment of
8 outcomes and learnings following the initial trial and consists of evidence-based
9 implementation and sustainability strategies.
- 10 • The stepped-wedge cluster study design is appropriate for implementation trials that
11 deliver implementation support at a service level and offers pragmatic and scientific
12 strengths to the study.
- 13 • Data will be collected through surveys of women who recently attended an antenatal
14 appointment, which is subject to less response bias than health-professional self-report
15 of clinical adherence and provides complete outcome data unlike medical records.
- 16 • The order in which the sectors receive the implementation support package will be non-
17 randomised.

1 INTRODUCTION

2 Alcohol consumption during pregnancy can lead to adverse obstetric (risk of placental
3 abruption, miscarriage and preterm birth¹⁻³) and child outcomes (birth defects, developmental
4 delays and Fetal Alcohol Spectrum Disorder⁴⁻⁶). Many countries have released guidelines that
5 recommend no alcohol consumption in pregnancy.⁷ Despite such recommendations, the global
6 prevalence of alcohol consumption during pregnancy has been estimated at 10%, with higher
7 prevalence estimates reported in a number of high income countries, including Ireland (60%),
8 Denmark (46%), United Kingdom (41%) and Australia (36%).⁸

9
10 Systematic review evidence shows that pregnant women who receive brief psychosocial
11 interventions from healthcare providers are more than twice as likely not to consume alcohol
12 during pregnancy (OR: 2.31; 95% CI: 1.61, 3.32; $p < 0.001$).⁹ Consistent with such evidence,
13 clinical guidelines recommend that all women at initial and subsequent antenatal appointments
14 receive: i) assessment of alcohol consumption; ii) advice not to consume alcohol and discussion
15 of the risks; and iii) referral to further support if required.^{10 11} Public maternity services are a
16 critical setting for these guidelines to be implemented as they provide care to the majority of
17 pregnant women in many countries, including Australia.^{12 13} However, clinician adherence to
18 the guideline recommendations in these services is low (assessment: 42%-64%;¹⁴⁻¹⁶ advice:
19 11%-35%;^{16 17} referral: 10-50%;^{16 18} and all guideline elements: 4%-28%¹⁶).

20
21 Two controlled trials to date have tested the effectiveness of implementation strategies in
22 increasing the provision of antenatal care addressing alcohol consumption during pregnancy.¹⁹

23 ²⁰ The first trial conducted in 2013 with four Italian Obstetrics and Gynaecology Units found
24 that training significantly increased the proportion of pregnant women who received guideline
25 consistent alcohol advice from their midwife (intervention: 53% vs control: 20%; RR: 2.66;

1 95% CI: 1.27, 5.56).¹⁹ The second trial, conducted with all public maternity services in three
2 sectors of a single local health district in Australia between 2017 and 2020, found that an
3 implementation support package consisting of seven evidence-based strategies significantly
4 increased the proportion of pregnant women who reported receipt of: assessment of alcohol
5 consumption via the Alcohol Use Disorders Identification Test—Consumption (AUDIT-C)
6 tool (pre-implementation: 28.4%; post-implementation: 40.6%; OR: 2.63; 95% CI: 2.26, 3.05;
7 $p < 0.001$); advice not to consume alcohol and discussion of the potential risks (pre-
8 implementation: 18.7%; post-implementation: 26.7%; OR: 2.07; 95% CI: 1.78, 2.41; $p < 0.001$);
9 complete care (advice and referral) relative to women's alcohol risk level (pre-implementation:
10 18.5%; post-implementation: 26.6%; OR: 2.10; 95% CI: 1.80, 2.44; $p < 0.001$); and all guideline
11 elements (assessment, advice and referral) relative to alcohol risk level (pre-implementation:
12 12.6%; post-implementation: 19.4%; OR: 2.32; 95% CI: 1.94, 2.76; $p < 0.001$).²⁰ The effect
13 sizes in both studies were at the upper end of implementation trial outcomes as reported in
14 Cochrane systematic reviews.²¹⁻³⁰ However, half or fewer reported receipt of the recommended
15 care elements after implementation support, leaving many women without the intended
16 benefits of the clinical guidelines. Such a finding is consistent with the clinical practice change
17 literature generally, which indicates that despite significant effect sizes in trials, the
18 interventions do not result in the majority of patients receiving guideline recommended care.
19
20 Improvements in healthcare are rarely breakthrough in nature, rather they tend to occur
21 gradually as new evidence is generated and applied.³¹ This is evident in quality improvement
22 approaches used in healthcare settings to improve processes, safety and patient care
23 outcomes.³² In such approaches, systematic modifications are iteratively made until
24 stakeholder defined outcomes are met and/or sustained practices are achieved.³³
25 Implementation trials that have used such approaches have demonstrated improvements in the

1 proportion of patients receiving evidence-based interventions, including smoking cessation
2 counselling in general practice³⁴ and HIV viral load monitoring in antenatal care.³⁵

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
There has been one study to date that has used an iterative improvement approach to increase the proportion of pregnant women receiving antenatal care addressing alcohol consumption during pregnancy.³⁶ Fifty Australian primary health care centres participated in four cycles of continuous quality improvement between 2007 and 2012 to improve pregnancy care for Aboriginal and Torres Strait Islander women. At the beginning of each cycle, a systems assessment and audit of patient records was conducted to identify opportunities for improvement. A longitudinal analysis of 2220 pregnancy records found that effects continued to increase for alcohol screening (cycle 1 OR: 2.6; 95% CI: 2.0, 3.5; cycle 4 OR: 3.9; 95% CI: 2.2, 7.1) and brief counselling (cycle 1 OR: 2.8; 95% CI: 1.7, 4.5; cycle 4 OR: 6.7; 95% CI: 2.3, 20.0) over the four cycles compared to baseline. Over the duration of the study, care provision increased by 18% for screening (65% to 83%) and 20% for counselling (51% to 71%).³⁶ The study, however, was non-controlled and the generalisability of results to the public hospital maternity service setting and non-Indigenous populations is unknown.

18 A further limitation of successful controlled implementation trials generally, is that observed
19 effect sizes do not persist.³⁷ For example, in the Australian controlled trial described above, a
20 time series analysis that explored the rate of weekly change in recommended alcohol care
21 delivery outcomes for 17 months after the implementation found significant decreases in both
22 assessment (-0.66%; 95% CI: -1.1, -0.26; p=0.002) and complete care (-0.64%; 95% CI: -1.1,
23 -0.22; p=0.003).²⁰ No specific sustainability strategies were incorporated into the
24 implementation support package delivered in the trial. This suggests that factors that commonly
25 impede sustainment of care delivery change may not have been sufficiently addressed by the

1 trial implementation support package³⁸ and that specific sustainability strategies may be
2 required to ensure achieved effect sizes are maintained.³⁹ A limited number of studies have
3 tested the effect of sustainability strategies in maintaining improvements in evidence-based
4 interventions in maternity service settings,^{40 41} with none specific to alcohol care. Such studies
5 have found maintenance of workforce skills through ongoing training and mentoring
6 opportunities, leadership buy-in and reviews of progress against improvement goals have
7 sustained improvements in a range of antenatal care practices for periods between one and five
8 years.^{40 41}

9
10 The need to find effective strategies to both improve and sustain the routine provision of
11 antenatal care addressing alcohol consumption during pregnancy remains. Given the potential
12 of an iterative care delivery improvement approach and the inclusion of specific sustainment
13 strategies to achieve this, and the limited research to date testing the effectiveness of such
14 approaches, an implementation trial will be conducted to assess the effectiveness of an
15 implementation support package including such approaches in: i) increasing the proportion of
16 pregnant women who receive guideline recommended antenatal care addressing alcohol
17 consumption; and ii) sustaining the rate of care over time.

18 19 **METHODS AND ANALYSIS**

20 The study methods were developed in accordance with the Standard Protocol Items:
21 Recommendations for Interventional Trials (Additional File 1).

22 23 **Study design and setting**

24 This trial follows on from a randomised stepped-wedge cluster trial that was conducted in
25 public maternity services in three sectors within the Hunter New England Local Health District

1
2
3 1 (HNELHD), New South Wales, Australia, between 2017 and 2020 (referred as the ‘initial trial’
4
5 2 from this point forward).²⁰ This trial will also use a stepped-wedge cluster study design and be
6
7 3 conducted with the same services that participated in the initial trial to further enhance care
8
9 4 delivery. The stepped-wedge cluster study design provides scientific and pragmatic advantages
10
11 5 for conducting implementations trials in health settings, including: providing the same level of
12
13 6 evidence as standard parallel cluster controlled trials; addressing the practical difficulty of
14
15 7 recruiting enough equivalent maternity services required for parallel cluster controlled trials;
16
17 8 and increasing study efficiency by using each group as its own control.^{42 43}
18
19
20
21
22
23

24 10 As shown in Figure 1, continuous cross-sectional outcome data will be collected with weekly
25
26 11 random samples of pregnant women who have recently attended an antenatal appointment with
27
28 12 a participating maternity service. Delivery of a three-month implementation support package
29
30 13 will occur sequentially at the three sectors, which will provide outcome data periods of variable
31
32 14 lengths for each sector. As per the initial trial, the intervention effect for aim one will be
33
34 15 determined by comparing the overall proportion of women who report recommended care
35
36 16 between pre-implementation and post-implementation periods for the three sectors combined.
37
38 17 This will be assessed six months after implementation completion in the last sector. For aim
39
40 18 two, an additional four months of post-implementation data will be collected for all three
41
42 19 sectors to allow for a more prolonged assessment of care delivery sustainment. The primary
43
44 20 outcomes will be re-analysed using a multiple baseline design to explore the rate of change
45
46 21 over time as the measure of sustainment.
47
48
49
50
51
52

53 23 The study is being conducted in three geographically and administratively distinct sectors. The
54
55 24 maternity services within these sectors provide antenatal care to 6,100 women annually (70%
56
57
58
59
60

1 of births in the district). Sectors One and Two are located in regional/rural areas (1200 and 600
2 births respectively) and Sector Three in a major city (4300 births per annum).⁴⁴

3
4
5
6
7
8
9
10 **(Insert Figure 1 here)**
11
12

13 **Participant blinding**

14
15
16
17 Research staff collecting outcome data will be blind to the order in which the three sectors
18 receive the implementation support package. Participants will not be informed of the
19 experimental nature of the implementation rollout and therefore will be blind to the stage of
20 the study in the maternity service they attend. Given that maternity service staff will receive
21 the implementation support package, they will be aware when their service is in the
22 implementation period.
23
24
25
26
27
28
29
30
31
32

33 **Participant eligibility and recruitment**

34 ***Maternity services and staff***

35
36
37 As per the initial trial, all maternity services within the three sectors will receive the
38 implementation support package. These services include: midwifery led services and clinics;
39 medical led clinics; and Aboriginal Maternal Infant Health Services (AMIHS). All antenatal
40 care providers in these services (midwifery and medical staff and Aboriginal Health Workers)
41 will be eligible to receive implementation support. This trial will also extend to maternity
42 service staff who are in positions that support the ongoing availability and usage of the
43 implementation strategies (maternity unit managers, administrative staff and clinical midwifery
44 educators (CMEs)). All antenatal care providers will be invited to participate in surveys prior
45 to implementation. All maternity service staff targeted to receive the implementation support
46 package will be invited to participate in post-implementation surveys.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1
4
5
6 2***Pregnant women***

7 3 All women who attend an antenatal appointment at a participating maternity service have the
8 4 potential to receive assessment and care addressing alcohol consumption as part of usual
9 5 antenatal care. Women are eligible to participate in data collection following attendance at
10 6 their: i) initial antenatal appointment; or ii) 27-28 weeks gestation appointment; or iii) 35-36
11 7 weeks gestation appointment. Further eligibility criteria: aged 18 years or older; 12-37 weeks
12 8 gestation; sufficient level of English to complete the survey; and mentally and physically
13 9 capable of completing the survey. Ineligibility criteria: receiving the majority of antenatal care
14 10 through a private provider; given birth; negative pregnancy outcome; selected to participate in
15 11 the data collection in the preceding four weeks; or previously declined participation in the
16 12 surveys. The number and characteristics of women deemed ineligible will be reported.

13

14 14 Each week, all eligible women from Sector One and Sector Two will be sampled. For Sector
15 15 Three, a random sample of eligible women will be generated via a computerised random-
16 16 number generator by members of the research team not involved in delivering care to women.
17 17 All women will be sampled in Sector One and Sector Two given the smaller number of women
18 18 who attend these services. To enhance representativeness of the data collected, all women who
19 19 are identified in the medical record data as being of Aboriginal and/or Torres Strait Islander
20 20 origin (the term Aboriginal will be used from this point) and women who are attending or
21 21 enrolled to attend an AMIHS will also be selected.

22

23 23 All women will receive a study information flyer in their usual antenatal information packs.
24 24 Selected women will be sent a participant information statement outlining the purpose of the
25 25 survey one week prior to receiving a telephone call inviting participation in the survey.

1
2
3 1 Aboriginal women and/or women attending or enrolled to attend an AMIHS will be contacted
4
5 2 by text message three days after the information statement is sent and invited to participate in
6
7 3 the survey via telephone or online modes. If no response is received, a telephone call will be
8
9 4 attempted four days later. On the day that a woman is to be contacted to invite participation,
10
11 5 medical record data will be checked and any women who have given birth or had a negative
12
13 6 pregnancy outcome will be deemed ineligible.
14
15
16
17
18

19 8 **Model of care and implementation support package**

20 9 *Evidence-based model of antenatal care*

21
22
23
24 10 The evidence^{9 45} and guideline-based^{10 11} model of antenatal care found to be acceptable to
25
26 11 Aboriginal (95%) and non-Aboriginal pregnant women (99%) and to antenatal care providers
27
28 12 (78% - 91%) in the initial trial²⁰ will be delivered to all pregnant women attending an initial
29
30 13 antenatal appointment, 27-29 weeks and 35-37 weeks antenatal appointment (Figure 2). The
31
32 14 model of care consists of three key elements:

- 33
34
35 15 • Assess: Assess all women's alcohol consumption using the AUDIT-C tool.⁴⁶ Women's
36
37 16 responses will be used to assign a risk of harm category: no risk (AUDIT-C score = 0);
38
39 17 low risk (AUDIT-C score = 1-2); medium risk (AUDIT-C score = 3-4); and high risk
40
41 18 (AUDIT-C score = 5+).
- 42
43
44 19 • Advise: Advise all women not to consume alcohol during pregnancy and discuss the
45
46 20 potential risks.
- 47
48
49 21 • Refer: Offer women at medium risk a referral to the free government funded Get
50
51 22 Healthy in Pregnancy telephone-based coaching service, which supports women to
52
53 23 make positive changes to their health, including abstaining from alcohol during
54
55 24 pregnancy.⁴⁷ Also offer Aboriginal women at medium risk a referral to counselling
56
57 25 services delivered through local Aboriginal Community Controlled Health Services
58
59
60

1
2
3 1 (ACCHS). Offer women at high risk a referral to HNELHD Drug and Alcohol Clinical
4
5 2 Services, which provide assessment, brief intervention and withdrawal support as
6
7 3 clinically indicated.
8
9
10 4

11
12 5 **(Insert Figure 2 here)**
13
14 6

15
16
17 7 ***Implementation support package***
18

19 8 The initial trial delivered a comprehensive implementation support package that sought to
20
21 9 increase the proportion of pregnant women receiving all elements of the model of antenatal
22
23 10 care. As the majority of pregnant women in that trial (89.0%) were found to have been asked
24
25 11 about alcohol consumption at the initial antenatal appointment, the implementation support
26
27 12 package in this trial will not specifically seek to improve this care element.²⁰ The trial
28
29 13 implementation support package will incorporate strategies that specifically address its two
30
31 14 aims based on an assessment of outcomes and learnings from the initial trial. See Figure 3 for
32
33 15 a description of the implementation support packages used in the initial trial and those proposed
34
35 16 for this trial, and Figure 4 for the logic model of this trial.
36
37
38
39
40
41

42 18 *Strategies to increase the proportion of pregnant women who receive antenatal care*
43
44 19 *addressing alcohol consumption*
45

46
47 20 In the initial trial, formative research using the Theoretical Domains Framework (TDF)^{48 49} was
48
49 21 conducted to comprehensively assess a range of barriers to implementing the recommended
50
51 22 model of care. To address change in barriers (or their relative importance) over time, surveys
52
53 23 were conducted with antenatal providers in the three sectors following completion of the trial
54
55 24 to identify the highest priority barrier/s to delivering two care elements (assessment at
56
57 25 subsequent antenatal appointments and advice discussion) using a best-worst scaling method.⁵⁰
58
59
60

1
2
3 1 Two priority barriers were found: i) forgetting; and ii) not believing there is a need to provide
4
5 2 alcohol focused care to all women. Forgetting had been identified as a barrier in the initial
6
7 3 formative research using the TDF, but its relative importance amongst all identified barriers
8
9 4 had not been ascertained due to the survey method utilised. Not believing in the need to provide
10
11 5 alcohol focused care to all women was not previously identified.
12
13
14
15
16

17 7 Similar to the initial trial, the priority barriers were defined in terms of the TDF^{48 49} and
18
19 8 Capacity, Opportunity, Motivation-Behaviours (COM-B) model⁵¹ and mapped to intervention
20
21 9 functions and Behaviour Change Techniques (BCTs) using the Behaviour Change Wheel.⁵¹
22
23 10 Process evaluation data collected in the initial trial was used to inform the delivery of the
24
25 11 implementation strategies. Components of strategies that had achieved high level/wide reach
26
27 12 and were rated as acceptable and appropriate by antenatal providers were incorporated into the
28
29 13 delivery of strategies. Clinical representatives and Aboriginal health staff provided expertise
30
31 14 to finalise the strategies and embed cultural appropriateness for Aboriginal women (see
32
33 15 Additional File 2 for development of implementation strategies).
34
35
36
37
38
39

40 17 Based on the above intervention development methods, the following strategies, defined
41
42 18 according to the Expert Recommendations for Implementing Change (ERIC) taxonomy,⁵² will
43
44 19 be delivered: remind clinicians; facilitation; and conduct educational meetings. The initial trial
45
46 20 implemented reminders as a strategy built into the electronic medical record system. This
47
48 21 strategy did not reach all maternity service types (e.g. home visits) and profession types (e.g.
49
50 22 some medical and Aboriginal Health staff did not use the electronic medical record system).
51
52 23 To address this, stickers for hard-copy medical records were implemented reactively during the
53
54 24 initial trial and were subsequently rated as the most useful resource by antenatal providers
55
56 25 (range: 72%-85%). The stickers, were primarily designed and used to record care provision
57
58
59
60

1 (rather than prompt) and only included assessment of alcohol consumption (not advice or
2 referral). Their availability and usage were also dependent on administrative staff who were
3 not provided with implementation support. These two issues will be addressed in the remind
4 clinicians strategy used in this trial.

5
6 Two additional implementation strategies (facilitation; conduct educational meetings) will
7 involve BCTs not used in the initial trial. A CME will deliver peer-to-peer facilitation to
8 support antenatal providers identify behavioural cues for providing assessment and care in the
9 clinical workflow of subsequent antenatal appointments. A CME will conduct educational
10 meetings that will utilise a credible source to deliver persuasive information on the harms of
11 alcohol consumption during pregnancy and provide new perspective on the purpose of
12 assessment of alcohol consumption at subsequent appointments and having advice discussions
13 with all women using framing/reframing techniques.⁵¹

15 *Strategies to sustain the rate of care over time*

16 A process for developing strategies to sustain the rate of care over time was undertaken guided
17 by principles of the Dynamic Sustainability Framework (DSF).⁵³ The DSF seeks to address
18 change in three areas: the evidence-based intervention (e.g. mode of delivery); practice setting
19 (e.g. information systems, training and staffing); and ecological systems (e.g. policies). To
20 determine the changes that had occurred in each of these areas since the initial trial,
21 consultations were undertaken with clinical representatives, and audits of antenatal schedules,
22 training records, staffing rosters, information systems, and resource and policy databases were
23 conducted.

24

1
2
3 1 Although it was found that there had been a marked increase in antenatal appointments
4
5 2 delivered via telehealth in response to the COVID-19 pandemic, telehealth care delivery
6
7 3 guidelines included alcohol care being delivered irrespective of appointment mode. An
8
9 4 assessment of systems and resources available to support care provision indicated that the
10
11 5 majority of strategies implemented in the initial trial were still fully or partially available. An
12
13 6 assessment of workforce turnover indicated that almost half of the current antenatal care
14
15 7 workforce was not employed at the time of the initial trial and almost half of these new staff
16
17 8 had not completed any of the training made available through the initial trial strategy. In
18
19 9 addition, no formal process that defined the roles and responsibilities of specific groups or staff
20
21 10 in ensuring the ongoing availability and use of supporting systems and resources, nor a formal
22
23 11 process for identifying when adaptations to the model of care and implementation strategies may
24
25 12 be required to address changes in circumstances. To address these factors, three strategies were
26
27 13 selected based on the sustainability literature and in consultation with experts in the field:
28
29 14 develop a formal implementation blueprint; purposely re-examine the implementation; and
30
31 15 conduct ongoing training⁵² (see Additional File 3 for development of strategies).
32
33
34
35
36
37
38
39

40 17 **(Insert Figure 3 here)**

41
42
43
44
45
46 20 **(Insert Figure 4 here)**

47 21 ***Implementation delivery timeline***

48
49 22 The implementation support package will be delivered in each of the sectors sequentially for a
50
51 23 period of three months (see Figure 1). Strategies aimed at increasing the proportion of women
52
53 24 who receive antenatal care addressing alcohol consumption will be delivered in the first two
54
55 25 months of the implementation. Strategies aimed at sustaining the rate of care will be developed,
56
57
58
59
60 26

1
2
3 1 agreed to, and implemented in the third month. Given the focus on embedding sustainability,
4
5 2 the implementation support package has the potential to continue supporting care provision
6
7 following the three-month implementation.
8
9

10 4 11 12 5 **Control and contamination**

13 14 6 *Usual Care*

15
16
17 7 In the pre-implementation data collection phase for each of the three sectors, usual antenatal
18
19 8 care for addressing alcohol consumption during pregnancy will be provided. Strategies
20
21 9 available to support care provision include: national and local clinical practice guidelines;
22
23 10 electronic medical record prompts; online education module; and performance data entered
24
25 11 into the health service's monitoring system quarterly. Care provision is likely to vary by
26
27 12 maternity service and clinician.
28
29
30

31 13 32 33 14 *Potential for contamination*

34
35 15 As the research team will control implementation delivery, the implementation support
36
37 16 package will not be accessible to maternity services during the pre-implementation (control)
38
39 17 phase.
40
41
42

43 18 44 45 19 **Patient and public involvement**

46
47 20 Pregnant women's acceptability of the model of care was considered in the development of the
48
49 21 evidence-based intervention for this trial. Antenatal care provider's feedback on the initial
50
51 22 implementation support package and new consultations with clinical representatives informed
52
53 23 the iterative development of this trial's support package. Consultations with Aboriginal health
54
55 24 staff were undertaken to embed cultural appropriateness for Aboriginal women across all
56
57 25 components of the trial. A Cultural Review Group containing only Aboriginal members,
58
59
60

1 including health service and community representatives, will review all dissemination
2 products.

3 4 **Measures**

5 *Primary trial outcomes*

6 The proportion of all pregnant women who report:

- 7 1. being asked about alcohol consumption at subsequent antenatal visits;
- 8 2. receiving complete care (advice and referral) relative to level of alcohol risk at
9 subsequent antenatal visits;
- 10 3. receiving complete care (advice and referral) relative to level of alcohol risk at the
11 initial antenatal visit.

12 13 *Process measures*

14 Fidelity, penetration/reach and acceptability will be assessed in accordance with the
15 implementation evaluation framework specified by Proctor et al.⁵⁴ Measures to assess
16 penetration/reach will include the proportion of eligible staff who were exposed to each of the
17 strategies. Acceptability of the strategies will be measured from the perspective of maternity
18 staff. Sustainment at the provider and inner-context levels will be measured from the
19 perspective of maternity staff using the three-item Provider REport of Sustainment Scale
20 (PRESS).⁵⁵ Changes occurring at the outer contextual level (e.g. social, political and economic
21 factors) that may influence practices will be monitored and reported.

22 23 *Within-trial economic analyses*

24 A trial-based cost-effectiveness analysis (CEA) will calculate the incremental cost per unit
25 change in the primary trial outcomes and cost-consequence analysis (CCA) will disaggregate

1
2
3 1 results by sector. To assess the affordability of sustaining care over time within the resource
4
5 2 and budget constraints of the health service, a Budget Impact Analysis (BIA) will also be
6
7 3 conducted. All analyses will be conducted and reported in accordance with the Consolidated
8
9 4 Health Economic Evaluation Reporting Standards (CHEERS) publication guidelines and good
10
11 5 reporting practices guidelines.⁵⁶
12
13
14
15
16

17 **Data collection procedures**

18 ***Primary outcome measures***

19
20
21 9 Telephone contact will be attempted with sampled women up to 10 times over a two-week
22
23 10 period in order to elicit consent and completion of the survey. Women who decline
24
25 11 participation in the telephone survey will be offered the online survey. Aboriginal women
26
27 12 and/or women attending or enrolled to attend AMIHS will be offered the choice of telephone
28
29 13 or online mode at first contact. The telephone survey will be computer assisted and be
30
31 14 conducted by trained female interviewers. The questions and response options will be identical
32
33 15 in the telephone and online surveys. All data collected will be recorded in the online Research
34
35 16 Electronic Data Capture (REDCap).^{57 58}
36
37
38
39
40
41

42 ***Process measures***

43
44 19 Process measures will be collected through surveys with maternity staff and project
45
46 20 management logs. Surveys of maternity service staff will be conducted pre-implementation
47
48 21 (sustainment only) and post-implementation in each sector (penetration/reach, acceptability
49
50 22 and sustainment). Eligible staff will be sent a link to an online survey via email as well as given
51
52 23 the option to complete the survey on tablet computers or pen and paper during regular clinic
53
54 24 meetings. Additional process data will be collected by project staff during the implementation
55
56 25 period and recorded in project management logs.
57
58
59
60

1
2
3 1
4
5
6 2**Costs**

3 Resource use associated with the implementation support package will be prospectively
4 identified, measured and valued using a cost capture template to be developed in REDCap.^{57,58}
5 Implementation resources are expected to include labour and materials to support maternity
6 service staff. Costs associated with implementation will be recorded separately from those used
7 for sustainability.

8
9**Sample size and power calculations**

10 Assuming that 225 women will complete a survey per month (approximately 150 for
11 subsequent antenatal visit time points and 75 for the initial antenatal visit time point), we will
12 have 80% power to detect an absolute increase of approximately (i) 15% in being asked about
13 alcohol consumption at subsequent antenatal visits (baseline prevalence of 42%); (ii) 13% in
14 complete care at subsequent antenatal visits (baseline prevalence of 23%); and (iii) 21% in
15 complete care at initial antenatal visits (baseline prevalence of 45%). This is assuming an ICC
16 of 0.01 and an alpha level of 1.67% (Bonferroni adjusted for the three primary outcomes).

17

Statistical Analyses

18 To address the first aim, pre-post differences in the proportion of women reporting receipt of
19 care for each of the three primary outcomes will be compared using generalised linear models
20 with a binomial distribution and logit link function. These models will compare the odds of
21 receiving care at post-implementation versus pre-implementation. Each model will contain a
22 term for period (pre or post implementation), sector (one, two, three), antenatal visit for the
23 outcomes on subsequent antenatal visits (28 weeks gestation, 36 weeks gestation) and time (in
24 months). An alpha level of 1.67% will be used to determine statistical significance. The odds
25

1
2
3 1 ratio and 95% confidence limit from the term for period will be presented as the intervention
4
5 2 effect.
6
7
8 3

9
10 4 For the second aim, segmented regression within an interrupted time-series framework will be
11
12 5 used to assess women's receipt of care over time, and whether this improves and sustains
13
14 6 following the delivery of the implementation support package. These analyses will be on the
15
16 7 same three primary outcomes assessed in the pre-post difference analyses and will be
17
18 8 conducted separately for each of the three sectors. Replication of findings across the three
19
20 9 sectors will provide greater confidence in the intervention effect.⁵⁹ Three segments will be
21
22 10 specified in each segmented regression, one for each of the study phases (i.e. pre-
23
24 11 implementation, implementation and post-implementation). The rate of change in the receipt
25
26 12 of care will be estimated for each of the three segments.
27
28
29
30
31 13

32
33 14 Exploratory secondary analyses will also be conducted to examine trial outcomes relative to
34
35 15 initial trial findings, including a comparison of the proportion of pregnant women receiving
36
37 16 guideline recommended care and rate of change per month of implementation support.
38
39
40 17

41 42 18 **Research trial governance**

43
44 19 The conduct of the trial will be overseen by an advisory group consisting of researchers,
45
46 20 practitioners and clinical experts with expertise related to alcohol consumption during
47
48 21 pregnancy, clinical practice change, sustainability, maternity services, Aboriginal health and
49
50 22 health economics. A project team consisting of research staff and a project dedicated CME will
51
52 23 operationalise all components of the trial according to study protocol.
53
54
55
56 24

57 58 25 **Aboriginal cultural governance**

59
60

1
2
3 1 Cultural governance will be embedded across the trial to be inclusive of Aboriginal people's
4
5 2 perspective. Aboriginal cultural task groups that are led by an Aboriginal project team member
6
7 3 will provide guidance on the delivery of the implementation support package. A Cultural
8
9 4 Review Group containing only Aboriginal members will review all dissemination products.
10
11
12
13
14

15 6 **Trial status**

16
17 7 Recruitment of Sector One will commence April 2022 and recruitment of the last Sector will
18
19 8 be completed in December 2022. Data collection will be completed by December 2023 and
20
21 9 data analysis will commence January 2024.
22
23
24
25

26 11 **ETHICS AND DISSEMINATION**

27
28 12 Ethical approval was obtained through the Hunter New England Human Research Ethics
29
30 13 Committee (16/11/16/4.07, 16/10/19/5.15); the University of Newcastle Human Research
31
32 14 Ethics Committee (H-2017-0032, H-2016-0422) and the Aboriginal Health and Medical
33
34 15 Research Council (1236/16). Any modifications to the protocol will be submitted to the
35
36 16 abovementioned ethics committees for approval prior to implementation. There are no pre-
37
38 17 determined criteria for trial discontinuation. Any unforeseen adverse events will be reported to
39
40 18 the Hunter New England Human Research Ethics Committee (primary approval committee).
41
42 19 The trial registry will be updated with any protocol modifications and any deviations from the
43
44 20 original protocol will be reported.
45
46
47
48
49
50

51 22 Participation in the women and staff surveys will be voluntary. Potential participants will
52
53 23 receive information about the study prior to providing verbal informed consent for surveys
54
55 24 conducted via phone or written consent for surveys completed via online/pen paper modes.
56
57 25 Women will have the opportunity to decline participation at any point, including after receiving
58
59
60

1 the study information flyer or participant letter; at the time of the telephone call or text message;
2 or partway through survey completion. Staff will also have the opportunity to decline
3 participation at any point. A data management protocol that was developed and approved by
4 the advisory group for the initial trial will be used in this trial. All data will be stored securely
5 as per the requirements of the approving ethics committees and confidential identifying
6 participant information will not be linked to survey responses. Data will only be accessible to
7 the project team.

8
9 Trial findings will be disseminated to health service decision makers to inform the feasibility
10 of conducting additional cycles to further improve antenatal care addressing alcohol
11 consumption. Findings will also inform the use of iterative improvement approaches for other
12 antenatal care guidelines in maternity services that have low adherence. Trial findings will be
13 disseminated to key stakeholder groups, including clinical representatives and Aboriginal
14 partners and community organisations. Lastly, outcomes will be disseminated through peer-
15 reviewed publications and at national and international conferences.

16
17 **Author contributions:** ED, MK, NN, AH and JW led the overall development of the research
18 protocol and ED led the development of the manuscript. JW, LW, MK and ED contributed to
19 the development of the rationale and background for the protocol. ED, LW, MK, NN, AH and
20 TM contributed to the development of the implementation support package. BT facilitated the
21 provision of cultural advice and establishment of cultural governance structures. IS contributed
22 clinical expertise relevant to the maternity services setting. EJE, AD and TWT contributed
23 clinical expertise relevant to alcohol consumption in pregnancy. ED and MK contributed to the
24 development of data collection methods generally and PR and OW contributed to the
25 development of data collection methods specific to the cost and cost effectiveness measures.

1
2
3 1 AH and JA provided overall guidance for the study design and data analysis. All authors read
4
5 2 and approved the final manuscript.
6
7
8 3
9

10 4 **Funding:** This research received no specific grant from any funding agency in the public,
11
12 5 commercial or not-for-profit sectors.
13
14 6
15
16

17 7 **Competing interests:** None declared.
18
19 8
20
21 9
22
23
24 10
25
26 11
27
28 12
29
30 13
31
32 14
33
34 15
35
36 16
37
38 17
39
40 18
41
42 19
43
44 20
45
46 21
47
48 22
49
50 23
51
52 24
53
54 25
55
56
57
58
59
60

1 REFERENCES

1. Steane SE, Young SL, Clifton VL, et al. Prenatal alcohol consumption and placental outcomes: a systematic review and meta-analysis of clinical studies. *American Journal of Obstetrics & Gynecology* 2021;26:26. doi: <https://dx.doi.org/10.1016/j.ajog.2021.06.078>
2. Sundermann AC, Zhao S, Young CL, et al. Alcohol Use in Pregnancy and Miscarriage: A Systematic Review and Meta-Analysis. *Alcoholism: Clinical & Experimental Research* 2019;43(8):1606-16. doi: <https://dx.doi.org/10.1111/acer.14124>
3. Patra J, Bakker R, Irving H, et al. Dose-response relationship between alcohol consumption before and during pregnancy and the risks of low birthweight, preterm birth and small for gestational age (SGA)-a systematic review and meta-analyses. *BJOG: An International Journal of Obstetrics & Gynaecology* 2011;118(12):1411-21.
4. Henderson J, Gray R, Brocklehurst P. Systematic review of effects of low-moderate prenatal alcohol exposure on pregnancy outcome. *BJOG : an international journal of obstetrics and gynaecology* 2007;114(3):243-52. doi: 10.1111/j.1471-0528.2006.01163.x
5. Flak AL, Su S, Bertrand J, et al. The association of mild, moderate, and binge prenatal alcohol exposure and child neuropsychological outcomes: a meta-analysis. *Alcohol Clin Exp Res* 2014;38(1):214-26. doi: <http://dx.doi.org/10.1111/acer.12214>
6. Lucas BR, Latimer J, Pinto RZ, et al. Gross motor deficits in children prenatally exposed to alcohol: a meta-analysis. *Pediatrics* 2014;134(1):e192-209. doi: <https://dx.doi.org/10.1542/peds.2013-3733>
7. National Health and Medical Research Council. Australian Guidelines to Reduce Health Risks from Drinking Alcohol. Canberra: Commonwealth of Australia, 2020.
8. Popova S, Lange S, Probst C, et al. Estimation of national, regional, and global prevalence of alcohol use during pregnancy and fetal alcohol syndrome: a systematic review and meta-analysis. *The Lancet Global Health* 2017;5(3):e290-e99. doi: [https://doi.org/10.1016/S2214-109X\(17\)30021-9](https://doi.org/10.1016/S2214-109X(17)30021-9)
9. Ujhelyi Gomez K, Goodwin L, Jackson L, et al. Are psychosocial interventions effective in reducing alcohol consumption during pregnancy and motherhood? A systematic review and meta-analysis. *Addiction* 2021;116(7):1638-63. doi: <https://dx.doi.org/10.1111/add.15296>
10. World Health Organisation. Guidelines for the identification and management of substance use and substance use disorders in pregnancy. Geneva: WHO 2014.
11. Department of Health. Clinical Practice Guidelines: Pregnancy Care - 2019 Edition. Canberra: Australian Government Department of Health, 2019.

12. Australian Government Department of Health. Improving Maternity Services in Australia. The Report of the Maternity Services Review. Canberra: Department of Health, 2009.
13. NHS Digital. NHS Maternity Statistics, England 2020-2021. NHS Digital, 2021.
14. Wangberg SC. Norwegian midwives' use of screening for and brief interventions on alcohol use in pregnancy. *Sexual & Reproductive Healthcare* 2015;6(3):186-90. doi: 10.1016/j.srhc.2015.03.001
15. Kesmodel U, Schiøler Kesmodel P. Drinking during pregnancy: attitudes and knowledge among pregnant Danish women, 1998. *Alcoholism: Clinical and Experimental Research* 2002;26(10):1553-60. doi: 10.1111/j.1530-0277.2002.tb02455.x
16. Doherty E, Wiggers J, Wolfenden L, et al. Antenatal care for alcohol consumption during pregnancy: pregnant women's reported receipt of care and associated characteristics. *BMC Pregnancy & Childbirth* 2019;19(1):299.
17. Kesmodel US, Kesmodel PS. Alcohol in pregnancy: attitudes, knowledge, and information practice among midwives in Denmark 2000 to 2009. *Alcohol Clin Exp Res* 2011;35(12):2226-30.
18. Waller A, Bryant J, Cameron E, et al. Women's perceptions of antenatal care: are we following guideline recommended care? *BMC Pregnancy and Childbirth* 2016;16(1):191. doi: 10.1186/s12884-016-0984-y
19. Bazzo S, Battistella G, Riscica P, et al. Evaluation of a Multilevel and Integrated Program to Raise Awareness of the Harmful Effects of Prenatal Alcohol Exposure in a Local Community. *Alcohol Alcohol* 2015;50(6):708-15. doi: <https://dx.doi.org/10.1093/alcalc/aggv051>
20. Doherty E, Kingsland M, Elliott EJ, et al. Practice change intervention to improve antenatal care addressing alcohol consumption during pregnancy: a randomised stepped-wedge controlled trial. *BMC Pregnancy and Childbirth* 2022; Accepted 30/03/2022.
21. Flodgren G, Parmelli E, Doumit G, et al. Local opinion leaders: effects on professional practice and health care outcomes. *Cochrane Syst Rev* 2011;8
22. Rotter T, Kinsman L, James EL, et al. Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. *Cochrane Syst Rev* 2010(3) doi: 10.1002/14651858.CD006632.pub2
23. Shojania et.al. The effects of on-screen, point of care computer reminders on processes and outcomes of care. *Cochrane Syst Rev* 2014(3: CD001096) doi: doi:10.1002/14651858.CD001096.pub2.

- 1
2
3 1 24. Woo K, Milworm G, Dowding D. Characteristics of Quality Improvement Champions in
4 2 Nursing Homes: A Systematic Review With Implications for Evidence-Based Practice.
5 3 *Worldviews on evidence-based nursing* 2017;14(6):440-46. doi: 10.1111/wvn.12262
6 4
7 8 25. Welsh SM, Sherriff A, Flodgren G. The champion for improved delivery of care to older
9 5 people in long-term care settings: effects on professional practice, quality of care and resident
10 6 outcomes. *Cochrane Syst Rev* 2015(11) doi: 10.1002/14651858.CD011956
11 7
12 8 26. Reeves S, Perrier L, Goldman J, et al. Interprofessional education: effects on professional
13 9 prac-tice and healthcare outcomes (update). *Cochrane Syst Rev* 2013;Issue 3:Art. No.:
14 10 CD002213.
15 11
16 12 27. Forsetlund L, Bjorndal A, Rashidian A, et al. Continuing education meetings and
17 13 workshops: effects on professional practice and health care outcomes. *Cochrane Syst Rev*
18 14 2009(2).
19 15
20 16 28. Chaillet N, Dube E, Dugas M, et al. Evidence-based strategies for implementing
21 17 guidelines in obstetrics: a systematic review. *Obstet Gynecol* 2006;108(5):1234-45. doi:
22 18 10.1097/01.AOG.0000236434.74160.8b
23 19
24 20 29. Ivers N, Jamtvedt G, Flottorp S. Audit and feedback: effects on professional practice and
25 21 healthcare outcomes. *Cochrane Syst Rev* 2012;Issue 6:Art. No.: CD000259.
26 22
27 23 30. O'Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: effects on
28 24 professional practice and health care outcomes. *Cochrane Syst Rev* 2007;4
29 25
30 26 31. McCrabb S, Mooney K, Elton B, et al. How to optimise public health interventions: a
31 27 scoping review of guidance from optimisation process frameworks. *BMC Public Health*
32 28 2020;20(1):1849. doi: <https://dx.doi.org/10.1186/s12889-020-09950-5>
33 29
34 30 32. O'Donnell B, Gupta V. Continuous Quality Improvement. *StatPearls Publishing*
35 31 2020;01:01.
36 32
37 33 33. Lynn J, Baily MA, Bottrell M, et al. The ethics of using quality improvement methods in
38 34 health care. *Annals of Internal Medicine* 2007;146(9):666-73.
39 35
40 36 34. Spencer E, Swanson T, Hueston WJ, et al. Tools to improve documentation of smoking
41 37 status. Continuous quality improvement and electronic medical records. *Archives of Family*
42 38 *Medicine* 1999;8(1):18-22.
43 39
44 40 35. Yapa HM, De Neve JW, Chetty T, et al. The impact of continuous quality improvement
45 41 on coverage of antenatal HIV care tests in rural South Africa: Results of a stepped-wedge
46 42 cluster-randomised controlled implementation trial. *PLoS Medicine / Public Library of*
47 43 *Science* 2020;17(10):e1003150. doi: <https://dx.doi.org/10.1371/journal.pmed.1003150>
48 44
49 45
50 46
51 47
52 48
53 49
54 50
55 51
56 52
57 53
58 54
59 55
60 56

- 1
2
3 1 36. Gibson-Helm ME, Rumbold AR, Teede HJ, et al. Improving the provision of pregnancy
4 2 care for Aboriginal and Torres Strait Islander women: a continuous quality improvement
5 3 initiative. *BMC Pregnancy & Childbirth* 2016;16:118. doi:
6 4 <https://dx.doi.org/10.1186/s12884-016-0892-1>
7 5
8 37. Ament SM, de Groot JJ, Maessen JM, et al. Sustainability of professionals' adherence to
9 6 clinical practice guidelines in medical care: a systematic review. *BMJ Open*
10 7 2015;5(12):e008073. doi: <https://dx.doi.org/10.1136/bmjopen-2015-008073>
11 8
12 38. Cowie J, Nicoll A, Dimova ED, et al. The barriers and facilitators influencing the
13 9 sustainability of hospital-based interventions: a systematic review. *BMC Health Services*
14 10 *Research* 2020;20(1):588. doi: <https://dx.doi.org/10.1186/s12913-020-05434-9>
15 11
16 39. Hailemariam M, Bustos T, Montgomery B, et al. Evidence-based intervention
17 12 sustainability strategies: a systematic review. *Implementation Science* 2019;14(1):57. doi:
18 13 <https://dx.doi.org/10.1186/s13012-019-0910-6>
19 14
20 40. Nahimana E, Magge H, Bizimana F, et al. Sustainability Assessment of a District-Wide
21 15 Quality Improvement on Newborn Care Program in Rural Rwanda: A Mixed-Method Study.
22 16 *Annals of Global Health* 2021;87(1):40. doi: <https://dx.doi.org/10.5334/aogh.3205>
23 17
24 41. Ahluwalia IB, Robinson D, Vallely L, et al. Sustainability of community-capacity to
25 18 promote safer motherhood in northwestern Tanzania: what remains? *Global Health*
26 19 *Promotion* 2010;17(1):39-49. doi: <https://dx.doi.org/10.1177/1757975909356627>
27 20
28 42. Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice
29 21 and healthcare outcomes. *Cochrane Syst Rev* 2012(6) doi:
30 22 10.1002/14651858.CD000259.pub3
31 23
32 43. Scott C, Andersen CT, Valdez N, et al. No global consensus: a cross-sectional survey of
33 24 maternal weight policies. *BMC Pregnancy Childbirth* 2014;14:167. doi: 10.1186/1471-2393-
34 25 14-167
35 26
36 44. New South Wales Ministry of Health, Centre for Epidemiology and Evidence. New South
37 27 Wales Mothers and Babies 2019 Report. Sydney: NSW Ministry of Health, 2021.
38 28
39 45. Stade BC, Bailey C, Dzenoletas D, et al. Psychological and/or educational interventions
40 29 for reducing alcohol consumption in pregnant women and women planning pregnancy.
41 30 *Cochrane syst rev* 2009(2):CD004228-CD28. doi: 10.1002/14651858.CD004228.pub2
42 31
43 46. Babor T F H-BJC, Saunders J B, Monteiro M G. AUDIT. The alcohol use disorders
44 32 identification test: Guidelines for use in primary care. World Health Organisation: Geneva,
45 33 2001.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 47. New South Wales Health. Get Healthy in Pregnancy [Available from:
4 <https://www.gethealthynsw.com.au/program/get-healthy-in-pregnancy/> Date accessed:
5 2
6 22/06/2018.
7 3
- 8 4 48. Atkins L, Francis J, Islam R, et al. A guide to using the Theoretical Domains Framework
9 of behaviour change to investigate implementation problems. *Implementation Science*
10 2017;12(1):77. doi: 10.1186/s13012-017-0605-9
11 5
- 12 6 49. French SD, Green SE, O'Connor DA, et al. Developing theory-informed behaviour
13 change interventions to implement evidence into practice: a systematic approach using the
14 Theoretical Domains Framework. *Implementation Science* 2012;7(1):1-8. doi: 10.1186/1748-
15 9
16 5908-7-38
17 10
- 18 11 50. Flynn TN. Valuing citizen and patient preferences in health: recent developments in three
19 types of best-worst scaling. *Expert Rev Pharmacoecon Outcomes Res* 2010;10(3):259-67.
20 12
21 doi: 10.1586/erp.10.29
22 13
- 23 14 51. Michie S, Johnston M, Francis J, et al. From Theory to Intervention: Mapping
24 Theoretically Derived Behavioural Determinants to Behaviour Change Techniques. *Applied*
25 *Psychology* 2008;57(4):660-80. doi: 10.1111/j.1464-0597.2008.00341.x
26 15
- 27 16 52. Powell BJ, Waltz TJ, Chinman MJ, et al. A refined compilation of implementation
28 strategies: results from the Expert Recommendations for Implementing Change (ERIC)
29 project. *Implementation Science* 2015;10:21.
30 17
- 31 18 53. Chambers DA, Glasgow RE, Stange KC. The dynamic sustainability framework:
32 addressing the paradox of sustainment amid ongoing change. *Implementation Science*
33 2013;8:117. doi: <https://dx.doi.org/10.1186/1748-5908-8-117>
34 20
- 35 21 54. Proctor E, Silmere H, Raghavan R, et al. Outcomes for Implementation Research:
36 Conceptual Distinctions, Measurement Challenges, and Research Agenda. *Administration*
37 *and Policy in Mental Health and Mental Health Services Research* 2011;38(2):65-76. doi:
38 22
39 10.1007/s10488-010-0319-7
40 23
- 41 24 55. Moullin JC, Sklar M, Ehrhart MG, et al. Provider REport of Sustainment Scale (PRESS):
42 development and validation of a brief measure of inner context sustainment. *Implementation*
43 *Science* 2021;16(1):86. doi: <https://dx.doi.org/10.1186/s13012-021-01152-w>
44 25
- 45 26 56. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation
46 Reporting Standards (CHEERS) statement. *BMJ: British Medical Journal* 2013;346:1049-55.
47 27
48 doi: 10.1136/bmj.f1049
49 28
- 50 29 57. Harris PA TR, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
51 capture (REDCap) - A metadata-driven methodology and workflow process for providing
52 30
53 31
54 32
55 33
56 34
57
58
59
60

- 1
2
3 1 translational research informatics support. *Journal of Biomedical Informatics*
4 2009;42(2):377-81.
5
6 58. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international
7 3 community of software platform partners. *Journal of biomedical informatics*
8 4 2019;95:103208.
9
10 59. Hawkins NG, Sanson-Fisher RW, Shakeshaft A, et al. The multiple baseline design for
11 6 evaluating population-based research. *American Journal of Preventive Medicine*
12 7 2007;33(2):162-8.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **FIGURE LEGENDS**

2 **Figure 1.** Data collection and study design

3

4 **Figure 2.** Evidence-based model of antenatal care recommended for provision at the initial and
5 subsequent antenatal appointments

6

7 **Figure 3.** Implementation support packages used in initial and current trial

8


9 **Figure 4.** Logic model

For peer review only

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 |
|-----------------|--|---|---|---|---|---|----------------|---|---|---------------------|----|----|---------------------|----|----|---------------------|----|----|----|----|----|----|----|----|----|----|----|
| | Continuous data collection via women's surveys | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Sector 1 | Pre-implementation | | | | | | Implementation | | | Post-implementation | | | | | | | | | | | | | | | | | |
| Sector 2 | Pre-implementation | | | | | | | | | Implementation | | | Post-implementation | | | | | | | | | | | | | | |
| Sector 3 | Pre-implementation | | | | | | | | | | | | Implementation | | | Post-implementation | | | | | | | | | | | |
| | Additional 4 months of data to assess sustainment using a multiple baseline design | | | | | | | | | | | | | | | | | | | | | | | | | | |

Peer review only

Downloaded from <http://bmjopen.bmj.com/> on April 7, 2024 by guest. Protected by copyright.




| Initial trial | |
|---|--|
| Strategies to increase the proportion of pregnant women who receive recommended care (7 months) | |
| Leadership/ managerial supervision | |
| Meetings were held every 2 months with maternity service management to elicit operational support for the practice change. | |
| Local clinical practice guidelines | |
| A service level guideline and procedure document that outlined the model of care (with local referral options) was uploaded onto the health service's policy and guidelines directory and disseminated. | |
| Remind clinicians | |
| Modifications were made to the existing point-of-care electronic medical record system used by maternity services. Antenatal providers were also provided with written point of care prompts. | |
| Local opinion leaders/ champions | |
| A dedicated CME was appointed in each sector to provide individual, team and service level support in the uptake of the recommended model of care. | |
| Educational meetings and educational materials | |
| A 30-minute online training module and a series of face-to-face sessions (including a mix of didactic, interactive, case-study, group and one-on-one sessions) (~1 hour) were facilitated by the CME. | |
| Academic detailing, including audit and feedback | |
| Data that were collected from medical records and surveys with pregnant women who recently attended a service were fed back to antenatal providers by the CME and used to develop action plans. | |
| Monitoring and accountability for performance | |
| Performance measures for the model of care for addressing alcohol consumption during pregnancy were included in managers' existing monitoring and accountability frameworks. | |
| Strategies to sustain the rate of care over time | |
| No specific sustainability strategies | |




| Current trial | |
|--|--|
| Strategies to increase the proportion of pregnant women who receive recommended care (2 months) | |
| Remind clinicians | |
| Point of care prompts will be included on women's hard-copy medical records. Prompts will fit with each service's usual clinical workflow and include a place to record that action was taken in the appointment. Staff who are usually responsible for resource ordering and medical record file management will receive instructive support. | |
| Facilitation | |
| A CME will facilitate peer-to-peer interactive problem solving to identify behavioural cues for providing assessment and care within the clinical workflow of antenatal appointments. Action plans that document the identified cues will be developed and examples included in training for new antenatal providers. | |
| Conduct educational meetings | |
| A single 15-minute educational meeting will be conducted. A credible source (Paediatrician with expertise in FASD) will provide persuasive education on the harms of alcohol consumption to increase salience of the issue. A CME will then guide a discussion focusing on reframing the purpose of providing assessment and care for alcohol consumption in antenatal visits. | |
| Strategies to sustain the rate of care over time (1 month) | |
| Develop a formal implementation blueprint | |
| A formal implementation blueprint that plans for sustainability will be developed. The plan will define the roles and responsibilities of maternity services and the supporting agency in sustaining implementation and ensuring the ongoing availability, use and maintenance of the strategies. | |
| Purposely re-examine the implementation | |
| A process for reviewing the formal implementation blueprint will be developed. The first review will occur at six months and provide a mechanism to identify whether adaptations to the model of care and strategies are required. | |
| Conduct ongoing training | |
| Existing CME's will receive support and resources to schedule and conduct orientation training for new staff and top-up training for existing staff (schedule to be determined by, and fit with, usual service training). | |

Aim One: Increase the proportion of pregnant women who receive antenatal care addressing alcohol consumption



Aim Two: Sustain the rate of care over time.





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

| Section/item | Item No | Description | Section |
|-----------------------------------|---------|--|--------------|
| Administrative information | | | |
| Title | 1 | Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym | Title page |
| Trial registration | 2a | Trial identifier and registry name. If not yet registered, name of intended registry | Abstract |
| | 2b | All items from the World Health Organization Trial Registration Data Set | Abstract |
| Protocol version | 3 | Date and version identifier | N/A |
| Funding | 4 | Sources and types of financial, material, and other support | Funding |
| Roles and responsibilities | 5a | Names, affiliations, and roles of protocol contributors | Contributors |
| | 5b | Name and contact information for the trial sponsor | N/A |
| | 5c | Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities | N/A |

36/bmjopen-2022-063486 on 26 July 2022. Downloaded from <http://bmjopen.bmj.com/> on April 7, 2024 by guest. Protected by copyright.

| | | | |
|----|---|-----|---|
| 1 | | | |
| 2 | | | |
| 3 | | | |
| 4 | | 5d | Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 7.1a for data monitoring committee) |
| 5 | | | Research trial governance and Aboriginal cultural governance |
| 6 | | | |
| 7 | | | |
| 8 | | | |
| 9 | | | |
| 10 | Introduction | | |
| 11 | | | |
| 12 | Background and rationale | 6a | Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention |
| 13 | | | Introduction |
| 14 | | | |
| 15 | | | |
| 16 | | 6b | Explanation for choice of comparators |
| 17 | | | Study design and setting |
| 18 | Objectives | 7 | Specific objectives or hypotheses |
| 19 | | | Introduction |
| 20 | Trial design | 8 | Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority equivalence, noninferiority, exploratory) |
| 21 | | | Study design and setting |
| 22 | | | |
| 23 | | | |
| 24 | | | |
| 25 | | | |
| 26 | Methods: Participants, interventions, and outcomes | | |
| 27 | | | |
| 28 | Study setting | 9 | Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained |
| 29 | | | Study design and setting |
| 30 | | | |
| 31 | | | |
| 32 | | | |
| 33 | Eligibility criteria | 10 | Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) |
| 34 | | | Participant eligibility and recruitment |
| 35 | | | |
| 36 | | | |
| 37 | Interventions | 11a | Interventions for each group with sufficient detail to allow replication, including how and when they will be administered |
| 38 | | | Model of care and implementation support package |
| 39 | | | |
| 40 | | | |
| 41 | | | |
| 42 | | | |
| 43 | | | |
| 44 | | | |
| 45 | | | |
| 46 | | | |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| | | | |
|----------------------|-----|--|---|
| | 11b | Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) | N/A |
| | 11c | Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) | Data collection procedures |
| | 11d | Relevant concomitant care and interventions that are permitted or prohibited during the trial | N/A |
| Outcomes | 12 | Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended | Measures |
| Participant timeline | 13 | Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) | Study design and setting |
| Sample size | 14 | Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations | Sample size and power calculations |
| Recruitment | 15 | Strategies for achieving adequate participant enrolment to reach target sample size | Participant eligibility and recruitment |

Methods: Assignment of interventions (for controlled trials)

Allocation:

36/bmjopen-2022-068886 on 26 June 2022. Downloaded from <http://bmjopen.bmj.com/> by guest. Protected by copyright.

| | | | | |
|----|---|-----|--|---|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | Sequence generation | 16a | Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions | N/A |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | Allocation concealment | 16b | Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned | N/A |
| 11 | mechanism | | | |
| 12 | | | | |
| 13 | | | | |
| 14 | | | | |
| 15 | Implementation | 16c | Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions | Participant eligibility and recruitment |
| 16 | | | | |
| 17 | | | | |
| 18 | Blinding (masking) | 17a | Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how | Participant blinding |
| 19 | | | | |
| 20 | | | | |
| 21 | | 17b | If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial | Participant blinding |
| 22 | | | | |
| 23 | | | | |
| 24 | | | | |
| 25 | Methods: Data collection, management, and analysis | | | |
| 26 | | | | |
| 27 | Data collection methods | 18a | Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol | Data collection procedures |
| 28 | | | | |
| 29 | | | | |
| 30 | | | | |
| 31 | | | | |
| 32 | | | | |
| 33 | | | | |
| 34 | | | | |
| 35 | | 18b | Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols | N/A |
| 36 | | | | |
| 37 | | | | |
| 38 | | | | |
| 39 | | | | |
| 40 | | | | |
| 41 | | | | |
| 42 | | | | |
| 43 | | | | |
| 44 | | | | |
| 45 | | | | |
| 46 | | | | |

| | | | | |
|----|----------------------------|-----|---|----------------------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | Data management | 19 | Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol | Data collection procedures |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | Statistical methods | 20a | Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol | Statistical Analyses |
| 10 | | | | |
| 11 | | | | |
| 12 | | | | |
| 13 | | | | |
| 14 | | 20b | Methods for any additional analyses (eg, subgroup and adjusted analyses) | Statistical Analyses |
| 15 | | | | |
| 16 | | 20c | Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | Methods: Monitoring | | | |
| 21 | | | | |
| 22 | Data monitoring | 21a | Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed | Ethics and dissemination |
| 23 | | | | |
| 24 | | | | |
| 25 | | | | |
| 26 | | | | |
| 27 | | | | |
| 28 | | | | |
| 29 | | 21b | Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial | Ethics and dissemination |
| 30 | | | | |
| 31 | | | | |
| 32 | | | | |
| 33 | | | | |
| 34 | Harms | 22 | Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct | Ethics and dissemination |
| 35 | | | | |
| 36 | | | | |
| 37 | | | | |
| 38 | | | | |
| 39 | | | | |
| 40 | | | | |
| 41 | | | | |
| 42 | | | | |
| 43 | | | | |
| 44 | | | | |
| 45 | | | | |
| 46 | | | | |

36/bmjopen-2022-068001 on 26 July 2022. Downloaded from <http://bmjopen.bmj.com/> by guest. Protected by copyright.

36/bmjopen-2022-066886 on 26 July 2022. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| | | | |
|---------------------------------|-----|---|--------------------------|
| Auditing | 23 | Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor | N/A |
| Ethics and dissemination | | | |
| Research ethics approval | 24 | Plans for seeking research ethics committee/institutional review board (REC/IRB) approval | Ethics and dissemination |
| Protocol amendments | 25 | Plans for communicating important protocol modifications (eg, change to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) | Ethics and dissemination |
| Consent or assent | 26a | Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) | Ethics and dissemination |
| | 26b | Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable | N/A |
| Confidentiality | 27 | How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial | Ethics and dissemination |
| Declaration of interests | 28 | Financial and other competing interests for principal investigators for the overall trial and each study site | Competing interests |
| Access to data | 29 | Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators | Ethics and dissemination |
| Ancillary and post-trial care | 30 | Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation | N/A |

| | | | |
|----------------------------|-----|---|--------------------------|
| Dissemination policy | 31a | Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions | Ethics and dissemination |
| | 31b | Authorship eligibility guidelines and any intended use of professional writers | Ethics and dissemination |
| | 31c | Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code | N/A |
| Appendices | | | |
| Informed consent materials | 32 | Model consent form and other related documentation given to participants and authorised surrogates | N/A |
| Biological specimens | 33 | Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable | N/A |

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

Additional File 2. Development of strategies to increase the proportion of pregnant women who receive assessment at subsequent antenatal visits and care at all antenatal visits.

| Priority barrier | COM-B (source of behaviour) & TDF domains | Intervention function | Behaviour Change Technique (BCT) | Mechanism of Action (MoA) | Implementation strategy [47] | Strategy description | Sustainability of technique |
|--|---|---|---|---|------------------------------|---|--|
| I forget to assess alcohol consumption at subsequent antenatal visits | COM-B: Physical opportunity TDF: Environmental context and resources | <ul style="list-style-type: none"> Environmental restructuring | <ul style="list-style-type: none"> Restructuring the physical environment Prompts, triggers, cues | <ul style="list-style-type: none"> Environmental context and resources Memory, attention and decision processes Behavioural cueing | Remind clinicians | <ul style="list-style-type: none"> Point of care prompts for assessment of alcohol consumption at subsequent antenatal visits and advice on the risks of alcohol consumption in pregnancy will be included on women's medical records. The placement of the prompts will fit with each service's usual clinical workflow. The prompts will include a place to record that action was taken in the visit. | Staff who are usually responsible for ordering resources and managing medical record files in each of the services will receive instruction in the ordering and placement of the prompts in the women's medical records. |
| I forget to explain the risks of alcohol consumption in pregnancy to all women | COM-B: Psychological capability TDF: Memory, attention and decision making | <ul style="list-style-type: none"> Enablement | <ul style="list-style-type: none"> Action planning | <ul style="list-style-type: none"> Behavioural cueing | Facilitation | <ul style="list-style-type: none"> A CME will facilitate a process of peer-to-peer interactive problem solving and support with antenatal providers to identify behavioural cues for providing assessment and care within antenatal visit clinical workflow. Action plans that document the identified cues in clinical workflow will be developed. | Examples of identified behavioural cues will be included in existing training and resources for new antenatal providers. |

| Priority barrier | COM-B (source of behaviour) & TDF domains | Intervention function | Behaviour Change Technique (BCT) | Mechanism of Action (MoA) | Implementation strategy [47] | Strategy description | Sustainability of technique |
|--|--|---|---|---|-------------------------------------|--|--|
| <p>I don't believe alcohol needs to be assessed at subsequent visits</p> <p>I don't believe the risks of alcohol consumption need to be explained to all women</p> | <p>COM-B: Reflective motivation</p> <p>TDF: Beliefs about consequences</p> | <ul style="list-style-type: none"> • Education • Persuasion | <ul style="list-style-type: none"> • Information about health consequences • Credible source • Framing/reframing | <ul style="list-style-type: none"> • Beliefs about consequences • Intention • Attitude towards the behaviour • Perceived susceptibility/vulnerability | <p>Conduct educational meetings</p> | <ul style="list-style-type: none"> • Information on the harms of alcohol consumption in pregnancy will be delivered by an expert in FASD. • A CME will guide a discussion with antenatal providers to reframe the purpose of providing assessment and care for alcohol consumption in multiple antenatal visits. | <p>Maternity services will be supported to incorporate this education into existing resources and schedules.</p> |

Additional File 3. Development of strategies to sustain the rate of care over time

| Factor potentially impacting sustainability | Sustainability strategy | Description |
|---|---|---|
| The roles and responsibilities of maternity services and support agencies in ensuring the ongoing availability and usage of the implementation strategies had not been formally defined | Develop a formal implementation blueprint | <ul style="list-style-type: none"> • A formal implementation blueprint that plans for sustainability will be developed and agreed to by maternity service leads in consultation with the supporting agency (Population Health Unit within the same Local Health District as the maternity services). • The plan will define the roles and responsibilities of maternity services in the continued provision of the model of care as part of routine practice. • The plan will define the roles and responsibilities of key maternity service groups/positions (maternity leadership, administrative staff, CME's) and the supporting agency in ensuring the ongoing availability, use and maintenance of the strategies implemented to support practice. |
| No process to review the fit of the model of care within current maternity service context and to audit the availability, usage and maintenance of the implementation strategies | Purposely re-examine the implementation | <ul style="list-style-type: none"> • A process for reviewing the formal implementation blueprint will be developed and agreed to by maternity service leads in consultation with the supporting agency. • The review will provide a mechanism to identify whether adaptations to the model of care and strategies supporting practice need to be made. • The first review will occur six months after the commencement of the intervention in each maternity service. |
| High staff turnover in maternity services | Conduct ongoing training | <ul style="list-style-type: none"> • Existing CME's in each of the services will receive support and resources to schedule and conduct orientation training for new staff and top-up training for existing staff. |

BMJ Open

Iterative delivery of an implementation support package to increase and sustain the routine provision of antenatal care addressing alcohol consumption during pregnancy: study protocol for a stepped-wedge cluster trial.

| | |
|-------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2022-063486.R1 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 07-Jul-2022 |
| Complete List of Authors: | <p>Doherty, Emma; The University of Newcastle College of Health Medicine and Wellbeing, School of Medicine and Public Health; Hunter New England Local Health District, Population Health</p> <p>Wiggers, John; The University of Newcastle College of Health Medicine and Wellbeing, School of Medicine and Public Health; Hunter New England Local Health District, Population Health</p> <p>Nathan, Nicole; The University of Newcastle College of Health Medicine and Wellbeing, School of Medicine and Public Health; Hunter New England Local Health District, Population Health</p> <p>Hall, Alix; The University of Newcastle College of Health Medicine and Wellbeing, School of Medicine and Public Health; Hunter New England Local Health District, Population Health</p> <p>Wolfenden, Luke; The University of Newcastle College of Health Medicine and Wellbeing, School of Medicine and Public Health; Hunter New England Local Health District, Population Health</p> <p>Tully, Belinda; Hunter New England Local Health District, Population Health</p> <p>Elliott, Elizabeth; The University of Sydney, Faculty of Medicine and Health and Discipline of Child and Adolescent Health; Sydney Children's Hospitals Network Randwick, Kids Research Institute</p> <p>Attia, John; The University of Newcastle Hunter Medical Research Institute; The University of Newcastle College of Health Medicine and Wellbeing, School of Medicine and Public Health</p> <p>Dunlop, Adrian; Hunter New England Local Health District, Drug and Alcohol Clinical Services Research</p> <p>Symonds, Ian; The University of Adelaide, Adelaide Medical School</p> <p>Tsang, Tracey; The University of Sydney, Faculty of Medicine and Health and Discipline of Child and Adolescent Health; Sydney Children's Hospitals Network Randwick, Kids Research Institute</p> <p>Reeves, Penny; The University of Newcastle Hunter Medical Research Institute, Health Research Economics</p> <p>McFadyen, Tameka; The University of Newcastle College of Health Medicine and Wellbeing, Thurru Indigenous Health Unit; Hunter New England Local Health District, Population Health</p> <p>Wynne, Olivia; The University of Newcastle College of Health Medicine and Wellbeing, School of Medicine and Public Health; Hunter New England Local Health District, Population Health</p> <p>Kingsland, Melanie; The University of Newcastle College of Health</p> |

| | |
|---------------------------------|---|
| | Medicine and Wellbeing, School of Medicine and Public Health; Hunter New England Local Health District, Population Health |
| Primary Subject Heading: | Health services research |
| Secondary Subject Heading: | Addiction, Obstetrics and gynaecology, Public health |
| Keywords: | Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Organisational development < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH, OBSTETRICS |
| | |

SCHOLARONE™
Manuscripts

1 **Title:** Iterative delivery of an implementation support package to increase and sustain the
2 routine provision of antenatal care addressing alcohol consumption during pregnancy: study
3 protocol for a stepped-wedge cluster trial.
4

5 **Author names:** Emma Doherty^{a,b,c}, John Wiggers^{a,b,c}, Nicole Nathan^{a,b,c}, Alix Hall^{a,b,c}, Luke
6 Wolfenden^{a,b,c}, Belinda Tully^a, Elizabeth J Elliott^{d,e}, John Attia^{b,c}, Adrian Dunlop^{b,f}, Ian
7 Symonds^g, Tracey W Tsang^{d,e}, Penny Reeves^c, Tameka McFadyen^{a,b,c}, Olivia Wynne^{a,b,c},
8 Melanie Kingsland^{a,b,c}.

9
10 ^a Population Health, Hunter New England Local Health District, Wallsend, New South Wales,
11 2287, Australia

12 ^b School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The
13 University of Newcastle, Callaghan, New South Wales, Australia

14 ^c Hunter Medical Research Institute, New Lambton Heights, New South Wales, 2305, Australia

15 ^d Faculty of Medicine and Health and Discipline of Child and Adolescent Health, The
16 University of Sydney, New South Wales, 2006, Australia

17 ^e Sydney Children's Hospital Network, Kids' Research Institute, Westmead, New South Wales,
18 2145, Australia

19 ^f Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle,
20 New South Wales, 2302, Australia

21 ^g Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, 5005,
22 Australia

23
24 **Corresponding author**

25 Emma Doherty

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Mail: co/ Hunter New England Population Health

2 Locked Bag 10, Wallsend NSW 2287, Australia

3 Email: emma.doherty@health.nsw.gov.au

For peer review only

1 **ABSTRACT**

2 **Introduction:** Antenatal care addressing alcohol consumption during pregnancy is not
3 routinely delivered in maternity services. Although a number of implementation trials have
4 reported significant increases in such care, the majority of women still did not receive all
5 recommended care elements, and improvements dissipated over time. This study aims to assess
6 the effectiveness of an iteratively developed and delivered implementation support package in:
7 i) increasing the proportion of pregnant women who receive antenatal care addressing alcohol
8 consumption; and ii) sustaining the rate of care over time.

9 **Methods and analysis:** A stepped-wedge cluster trial will be conducted as a second phase of
10 a previous trial. All public maternity services within three sectors of a local health district in
11 Australia will receive an implementation support package that was developed based on an
12 assessment of outcomes and learnings following the initial trial. The package will consist of
13 evidence-based strategies to support increases in care provision (remind clinicians; facilitation;
14 conduct educational meetings) and sustainment (develop a formal implementation blueprint;
15 purposely re-examine the implementation; conduct ongoing training). Measurement of
16 outcomes will occur via surveys with women who attend antenatal appointments each week.
17 Primary outcomes will be the proportion of women who report being asked about alcohol
18 consumption at subsequent antenatal appointments; and receiving complete care (advice and
19 referral) relative to alcohol risk at initial and subsequent antenatal appointments. Economic and
20 process evaluation measures will also be reported.

21 **Ethics and dissemination:** Ethical approval was obtained through the Hunter New England
22 (16/11/16/4.07, 16/10/19/5.15) and University of Newcastle Human Research Ethics
23 Committees (H-2017-0032, H-2016-0422) and the Aboriginal Health and Medical Research
24 Council (1236/16). Trial findings will be disseminated to health service decision makers to
25 inform the feasibility of conducting additional cycles to further improve antenatal care

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 addressing alcohol consumption as well as at scientific conferences and in peer-reviewed
2 journals.

3 Trial Registration: Australian and New Zealand Clinical Trials Registry,
4 ACTRN12622000295741 (16/02/2022)
5 <https://www.anzctr.org.au/ACTRN12622000295741.aspx>

6 **Keywords:** quality in healthcare, organisational development, protocols and guidelines, public
7 health, obstetrics

For peer review only

1 ARTICLE SUMMARY

2 Strengths and limitations of this study

- 3 • This will be the first controlled trial to evaluate the effectiveness of an iteratively
4 developed and delivered implementation support package in increasing and sustaining
5 the routine provision of antenatal care addressing alcohol consumption during
6 pregnancy.
- 7 • The implementation support package was developed based on an assessment of
8 outcomes and learnings following the initial trial and consists of evidence-based
9 implementation and sustainability strategies.
- 10 • The stepped-wedge cluster study design is appropriate for implementation trials that
11 deliver implementation support at a service level and offers pragmatic and scientific
12 strengths to the study.
- 13 • Data will be collected through surveys of women who recently attended an antenatal
14 appointment, which is subject to less response bias than health-professional self-report
15 of clinical adherence and provides complete outcome data unlike medical records.
- 16 • The order in which the sectors receive the implementation support package will be non-
17 randomised.

1 INTRODUCTION

2 Alcohol consumption during pregnancy can lead to adverse obstetric (risk of placental
3 abruption, miscarriage and preterm birth¹⁻³) and child outcomes (birth defects, developmental
4 delays and Fetal Alcohol Spectrum Disorder⁴⁻⁶). Many countries have released guidelines that
5 recommend no alcohol consumption in pregnancy.⁷ Despite such recommendations, the global
6 prevalence of alcohol consumption during pregnancy has been estimated at 10%, with higher
7 prevalence estimates reported in a number of high income countries, including Ireland (60%),
8 Denmark (46%), United Kingdom (41%) and Australia (36%).⁸

9
10 Systematic review evidence shows that pregnant women who receive brief psychosocial
11 interventions from healthcare providers are more than twice as likely not to consume alcohol
12 during pregnancy (OR: 2.31; 95% CI: 1.61, 3.32; $p < 0.001$).⁹ Consistent with such evidence,
13 clinical guidelines recommend that all women at initial and subsequent antenatal appointments
14 receive: i) assessment of alcohol consumption; ii) advice not to consume alcohol and discussion
15 of the risks; and iii) referral to specialist services for further assessment, diagnosis of alcohol
16 use disorders and treatment if required.^{10 11} Public maternity services are a critical setting for
17 these guidelines to be implemented as they provide care to the majority of pregnant women in
18 many countries, including Australia.^{12 13} However, clinician adherence to the guideline
19 recommendations in these services is low (assessment: 42%-64%;¹⁴⁻¹⁶ advice: 11%-35%;^{16 17}
20 referral: 10-50%;^{16 18} and all guideline elements: 4%-28%¹⁶).

21
22 Two controlled trials to date have tested the effectiveness of implementation strategies in
23 increasing the provision of antenatal care addressing alcohol consumption during pregnancy.¹⁹
24 ²⁰ The first trial conducted in 2013 with four Italian Obstetrics and Gynaecology Units found
25 that training significantly increased the proportion of pregnant women who received guideline

1 consistent alcohol advice from their midwife (intervention: 53% vs control: 20%; RR: 2.66;
2 95% CI: 1.27, 5.56).¹⁹ The second trial, conducted with all public maternity services in three
3 sectors of a single local health district in Australia between 2017 and 2020, found that an
4 implementation support package consisting of seven evidence-based strategies significantly
5 increased the proportion of pregnant women who reported receipt of: assessment of alcohol
6 consumption via the Alcohol Use Disorders Identification Test—Consumption (AUDIT-C)
7 tool (pre-implementation: 28.4%; post-implementation: 40.6%; OR: 2.63; 95% CI: 2.26, 3.05;
8 $p < 0.001$); advice not to consume alcohol and discussion of the potential risks (pre-
9 implementation: 18.7%; post-implementation: 26.7%; OR: 2.07; 95% CI: 1.78, 2.41; $p < 0.001$);
10 complete care (advice and referral) relative to women's alcohol risk level (pre-implementation:
11 18.5%; post-implementation: 26.6%; OR: 2.10; 95% CI: 1.80, 2.44; $p < 0.001$); and all guideline
12 elements (assessment, advice and referral) relative to alcohol risk level (pre-implementation:
13 12.6%; post-implementation: 19.4%; OR: 2.32; 95% CI: 1.94, 2.76; $p < 0.001$).²⁰ The effect
14 sizes in both studies were at the upper end of implementation trial outcomes as reported in
15 Cochrane systematic reviews.²¹⁻³⁰ However, half or fewer reported receipt of the recommended
16 care elements after implementation support, leaving many women without the intended
17 benefits of the clinical guidelines. Such a finding is consistent with the clinical practice change
18 literature generally, which indicates that despite significant effect sizes in trials, the
19 interventions do not result in the majority of patients receiving guideline recommended care.
20
21 Improvements in healthcare are rarely breakthrough in nature, rather they tend to occur
22 gradually as new evidence is generated and applied.³¹ Public health approaches to addressing
23 health risks recognise that multiple steps are required for improvements to occur (e.g. defining
24 the problem, understanding the determinants of the problem, designing strategies and
25 implementing/evaluating strategies) and that often such steps need to be repeated as the

1 evidence-base is built over time.³² This is also evident in quality improvement approaches used
2 in healthcare settings to improve processes, safety and patient care outcomes.³³ In such
3 approaches, systematic modifications are iteratively made until stakeholder defined outcomes
4 are met and/or sustained practices are achieved.³⁴ Implementation trials that have used such
5 approaches have demonstrated improvements in the proportion of patients receiving evidence-
6 based interventions, including smoking cessation counselling in general practice³⁵ and HIV
7 viral load monitoring in antenatal care.³⁶

8
9 There has been one study to date that has used an iterative improvement approach to increase
10 the proportion of pregnant women receiving antenatal care addressing alcohol consumption
11 during pregnancy.³⁷ Fifty Australian primary health care centres participated in four cycles of
12 continuous quality improvement between 2007 and 2012 to improve pregnancy care for
13 Aboriginal and Torres Strait Islander women. At the beginning of each cycle, a systems
14 assessment and audit of patient records was conducted to identify opportunities for
15 improvement. A longitudinal analysis of 2220 pregnancy records found that effects continued
16 to increase for alcohol screening (cycle 1 OR: 2.6; 95% CI: 2.0, 3.5; cycle 4 OR: 3.9; 95% CI:
17 2.2, 7.1) and brief counselling (cycle 1 OR: 2.8; 95% CI: 1.7, 4.5; cycle 4 OR: 6.7; 95% CI:
18 2.3, 20.0) over the four cycles compared to baseline. Over the duration of the study, care
19 provision increased by 18% for screening (65% to 83%) and 20% for counselling (51% to
20 71%).³⁷ The study, however, was non-controlled and the generalisability of results to the public
21 hospital maternity service setting and non-Indigenous populations is unknown.

22
23 A further limitation of successful controlled implementation trials generally, is that observed
24 effect sizes do not persist.³⁸ For example, in the Australian controlled trial described above, a
25 time series analysis that explored the rate of weekly change in recommended alcohol care

1
2
3 1 delivery outcomes for 17 months after the implementation found significant decreases in both
4
5 2 assessment (-0.66%; 95% CI: -1.1, -0.26; p=0.002) and complete care (-0.64%; 95% CI: -1.1,
6
7 -0.22; p=0.003).²⁰ No specific sustainability strategies were incorporated into the
8
9
10 4 implementation support package delivered in the trial. This suggests that factors that commonly
11
12 5 impede sustainment of care delivery change may not have been sufficiently addressed by the
13
14 6 trial implementation support package³⁹ and that specific sustainability strategies may be
15
16 7 required to ensure achieved effect sizes are maintained.⁴⁰ A limited number of studies have
17
18 8 tested the effect of sustainability strategies in maintaining improvements in evidence-based
19
20 9 interventions in maternity service settings,^{41 42} with none specific to alcohol care. Such studies
21
22 10 have found maintenance of workforce skills through ongoing training and mentoring
23
24 11 opportunities, leadership buy-in and reviews of progress against improvement goals have
25
26 12 sustained improvements in a range of antenatal care practices for periods between one and five
27
28 13 years.^{41 42}

29
30
31
32
33
34
35 15 The need to find effective strategies to both improve and sustain the routine provision of
36
37 16 antenatal care addressing alcohol consumption during pregnancy remains. Given the potential
38
39 17 of an iterative care delivery improvement approach and the inclusion of specific sustainment
40
41 18 strategies to achieve this, and the limited research to date testing the effectiveness of such
42
43 19 approaches, an implementation trial will be conducted to assess the effectiveness of an
44
45 20 implementation support package including such approaches in: i) increasing the proportion of
46
47 21 pregnant women who receive guideline recommended antenatal care addressing alcohol
48
49 22 consumption; and ii) sustaining the rate of care over time.

50 51 52 53 54 55 56 24 **METHODS AND ANALYSIS**

57
58
59
60

1
2
3 1 The study methods were developed in accordance with the Standard Protocol Items:
4
5 2 Recommendations for Interventional Trials (Additional File 1).
6
7
8 3

9
10 4 **Study design and setting**

11
12 5 This trial follows on from a randomised stepped-wedge cluster trial that was conducted in
13
14 6 public maternity services in three sectors within the Hunter New England Local Health District
15
16 7 (HNELHD), New South Wales, Australia, between 2017 and 2020 (referred as the ‘initial trial’
17
18 8 from this point forward).²⁰ This trial will also use a stepped-wedge cluster study design and be
19
20 9 conducted with the same services that participated in the initial trial to further enhance care
21
22 10 delivery. The stepped-wedge cluster study design provides scientific and pragmatic advantages
23
24 11 for conducting implementations trials in health settings, including: providing the same level of
25
26 12 evidence as standard parallel cluster controlled trials; addressing the practical difficulty of
27
28 13 recruiting enough equivalent maternity services required for parallel cluster controlled trials;
29
30 14 and increasing study efficiency by using each group as its own control.^{43 44}
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

16 As shown in Figure 1, continuous cross-sectional outcome data will be collected with weekly
17
18 random samples of pregnant women who have recently attended an antenatal appointment with
19
20 a participating maternity service. Delivery of a three-month implementation support package
21
22 will occur sequentially at the three sectors, which will provide outcome data periods of variable
23
24 lengths for each sector. As per the initial trial, the intervention effect for aim one will be
25
26 determined by comparing the overall proportion of women who report recommended care
27
28 between pre-implementation and post-implementation periods for the three sectors combined.
29
30 This will be assessed six months after implementation completion in the last sector. For aim
31
32 two, an additional four months of post-implementation data will be collected for all three
33
34 sectors to allow for a more prolonged assessment of care delivery sustainment. The primary

1 outcomes will be re-analysed using a multiple baseline design to explore the rate of change
2 over time as the measure of sustainment.

3
4 The study is being conducted in three geographically and administratively distinct sectors. The
5 maternity services within these sectors provide antenatal care to 6,100 women annually (70%
6 of births in the district). Sectors One and Two are located in regional/rural areas (1200 and 600
7 births respectively) and Sector Three in a major city (4300 births per annum).⁴⁵

8
9 **(Insert Figure 1 here)**

10 11 **Participant blinding**

12 Research staff collecting outcome data will be blind to the order in which the three sectors
13 receive the implementation support package. Participants will not be informed of the
14 experimental nature of the implementation rollout and therefore will be blind to the stage of
15 the study in the maternity service they attend. Given that maternity service staff will receive
16 the implementation support package, they will be aware when their service is in the
17 implementation period.

18 19 **Participant eligibility and recruitment**

20 ***Maternity services and staff***

21 As per the initial trial, all maternity services within the three sectors will receive the
22 implementation support package. These services include: midwifery led services and clinics;
23 medical led clinics; and Aboriginal Maternal Infant Health Services (AMIHS). All antenatal
24 care providers in these services (midwifery and medical staff and Aboriginal Health Workers)
25 will be eligible to receive implementation support. This trial will also extend to maternity

1
2
3 1 service staff who are in positions that support the ongoing availability and usage of the
4
5 2 implementation strategies (maternity unit managers, administrative staff and clinical midwifery
6
7 3 educators (CMEs)). All antenatal care providers will be invited to participate in surveys prior
8
9 4 to implementation. All maternity service staff targeted to receive the implementation support
10
11 5 package will be invited to participate in post-implementation surveys.
12
13
14
15
16

17 ***Pregnant women***

18
19 8 All women who attend an antenatal appointment at a participating maternity service have the
20
21 9 potential to receive assessment and care addressing alcohol consumption as part of usual
22
23 10 antenatal care. Women are eligible to participate in data collection following attendance at
24
25 11 their: i) initial antenatal appointment; or ii) 27-28 weeks gestation appointment; or iii) 35-36
26
27 12 weeks gestation appointment. Further eligibility criteria: aged 18 years or older; 12-37 weeks
28
29 13 gestation; sufficient level of English to complete the survey; and mentally and physically
30
31 14 capable of completing the survey. Ineligibility criteria: receiving the majority of antenatal care
32
33 15 through a private provider; given birth; negative pregnancy outcome; selected to participate in
34
35 16 the data collection in the preceding four weeks; or previously declined participation in the
36
37 17 surveys. The number and characteristics of women deemed ineligible will be reported.
38
39
40
41
42
43

44 19 Each week, all eligible women from Sector One and Sector Two will be sampled. For Sector
45
46 20 Three, a random sample of eligible women will be generated via a computerised random-
47
48 21 number generator by members of the research team not involved in delivering care to women.

49
50 22 All women will be sampled in Sector One and Sector Two given the smaller number of women
51
52 23 who attend these services. To enhance representativeness of the data collected, all women who
53
54 24 are identified in the medical record data as being of Aboriginal and/or Torres Strait Islander
55
56
57
58
59
60

1 origin (the term Aboriginal will be used from this point) and women who are attending or
2 enrolled to attend an AMIHS will also be selected.

3
4 All women will receive a study information flyer in their usual antenatal information packs.
5 Selected women will be sent a participant information statement outlining the purpose of the
6 survey one week prior to receiving a telephone call inviting participation in the survey. As per
7 advice from Aboriginal stakeholders regarding a culturally appropriate recruitment method for
8 Aboriginal women, Aboriginal women and/or women attending or enrolled to attend an
9 AMIHS will be contacted by text message three days after the information statement is sent
10 and invited to participate in the survey via telephone or online modes. If no response is
11 received, a telephone call will be attempted four days later. On the day that a woman is to be
12 contacted to invite participation, medical record data will be checked and any women who have
13 given birth or had a negative pregnancy outcome will be deemed ineligible.

15 **Model of care and implementation support package**

16 *Evidence-based model of antenatal care*

17 The evidence^{9 46} and guideline-based^{10 11} model of antenatal care found to be acceptable to
18 Aboriginal (95%) and non-Aboriginal pregnant women (99%) and to antenatal care providers
19 (78% - 91%) in the initial trial²⁰ will be delivered to all pregnant women attending an initial
20 antenatal appointment, 27-29 weeks and 35-37 weeks antenatal appointment (Figure 2). The
21 model of care is based on the Screening, Brief Intervention, and Referral to Treatment (SBIRT)
22 public health approach to the management of substance abuse⁴⁷ and consists of three key
23 elements:

- 24 • Assess: Assess all women's alcohol consumption using the AUDIT-C tool.⁴⁸ Women's
25 responses will be used to assign a risk of harm category: no risk (AUDIT-C score = 0);

- 1
2
3 1 low risk (AUDIT-C score = 1-2); medium risk (AUDIT-C score = 3-4); and high risk
4
5 2 (AUDIT-C score = 5+).
6
7
8 3 • Advise: Advise all women not to consume alcohol during pregnancy and discuss the
9
10 4 potential risks.
11
12 5 • Refer: Offer women at medium risk a referral to the free government funded Get
13
14 6 Healthy in Pregnancy telephone-based coaching service, which supports women to
15
16 7 make positive changes to their health, including abstaining from alcohol during
17
18 8 pregnancy.⁴⁹ Also offer Aboriginal women at medium risk a referral to counselling
19
20 9 services delivered through local Aboriginal Community Controlled Health Services
21
22 10 (ACCCHS). Offer women at high risk a referral to HNELHD Drug and Alcohol Clinical
23
24 11 Services, which provide further assessment and diagnosis of alcohol use disorders, brief
25
26 12 intervention, treatment and withdrawal support as clinically indicated.
27
28
29
30
31
32

33 **(Insert Figure 2 here)**
34
35
36
37

38 ***Implementation support package***

39
40 17 The initial trial delivered a comprehensive implementation support package that sought to
41
42 18 increase the proportion of pregnant women receiving all elements of the model of antenatal
43
44 19 care. As the majority of pregnant women in that trial (89.0%) were found to have been asked
45
46 20 about alcohol consumption at the initial antenatal appointment, the implementation support
47
48 21 package in this trial will not specifically seek to improve this care element.²⁰ The trial
49
50 22 implementation support package will incorporate strategies that specifically address its two
51
52 23 aims based on an assessment of outcomes and learnings from the initial trial. As per
53
54 24 implementation science recommendations,⁵⁰ the support package will be targeted to the
55
56 25 specific barriers and context of the local maternity service setting. See Figure 3 for a description
57
58
59
60

1 of the implementation support packages used in the initial trial and those proposed for this trial,
2 and Figure 4 for the logic model of this trial.

3
4 *Strategies to increase the proportion of pregnant women who receive antenatal care*
5 *addressing alcohol consumption*

6 In the initial trial, formative research using the Theoretical Domains Framework (TDF)^{51 52} was
7 conducted to comprehensively assess a range of barriers to implementing the recommended
8 model of care. To address change in barriers (or their relative importance) over time, surveys
9 were conducted with antenatal providers in the three sectors following completion of the trial
10 to identify the highest priority barrier/s to delivering two care elements (assessment at
11 subsequent antenatal appointments and advice discussion) using a best-worst scaling method.⁵³
12 Two priority barriers were found: i) forgetting; and ii) not believing there is a need to provide
13 alcohol focused care to all women. Forgetting had been identified as a barrier in the initial
14 formative research using the TDF, but its relative importance amongst all identified barriers
15 had not been ascertained due to the survey method utilised. Not believing in the need to provide
16 alcohol focused care to all women was not previously identified.

17
18 Similar to the initial trial, the priority barriers were defined in terms of the TDF^{51 52} and
19 Capacity, Opportunity, Motivation-Behaviours (COM-B) model⁵⁴ and mapped to intervention
20 functions and Behaviour Change Techniques (BCTs) using the Behaviour Change Wheel.⁵⁴
21 Process evaluation data collected in the initial trial was used to inform the delivery of the
22 implementation strategies. Components of strategies that had achieved high level/wide reach
23 and were rated as acceptable and appropriate by antenatal providers were incorporated into the
24 delivery of strategies. Clinical representatives and Aboriginal health staff provided expertise

1
2
3 1 to finalise the strategies and embed cultural appropriateness for Aboriginal women (see
4
5 2 Additional File 2 for development of implementation strategies).
6
7
8 3

9
10 4 Based on the above intervention development methods, the following strategies, defined
11
12 5 according to the Expert Recommendations for Implementing Change (ERIC) taxonomy,⁵⁵ will
13
14 6 be delivered: remind clinicians; facilitation; and conduct educational meetings. The initial trial
15
16 7 implemented reminders as a strategy built into the electronic medical record system. This
17
18 8 strategy did not reach all maternity service types (e.g. home visits) and profession types (e.g.
19
20 9 some medical and Aboriginal Health staff did not use the electronic medical record system).
21
22 10 To address this, stickers for hard-copy medical records were implemented reactively during the
23
24 11 initial trial and were subsequently rated as the most useful resource by antenatal providers
25
26 12 (range: 72%-85%). The stickers, were primarily designed and used to record care provision
27
28 13 (rather than prompt) and only included assessment of alcohol consumption (not advice or
29
30 14 referral). Their availability and usage were also dependent on administrative staff who were
31
32 15 not provided with implementation support. These two issues will be addressed in the remind
33
34 16 clinicians strategy used in this trial.
35
36
37
38
39
40
41

42 18 Two additional implementation strategies (facilitation; conduct educational meetings) will
43
44 19 involve BCTs not used in the initial trial. A CME will deliver peer-to-peer facilitation to
45
46 20 support antenatal providers identify behavioural cues for providing assessment and care in the
47
48 21 clinical workflow of subsequent antenatal appointments. A CME will conduct educational
49
50 22 meetings that will utilise a credible source to deliver persuasive information on the harms of
51
52 23 alcohol consumption during pregnancy and provide new perspective on the purpose of
53
54 24 assessment of alcohol consumption at subsequent appointments and having advice discussions
55
56 25 with all women using framing/reframing techniques.⁵⁴
57
58
59
60

1
2
3 1
4
5 2 *Strategies to sustain the rate of care over time*

6
7 3 A process for developing strategies to sustain the rate of care over time was undertaken guided
8
9 4 by principles of the Dynamic Sustainability Framework (DSF).⁵⁶ The DSF seeks to address
10
11 5 change in three areas: the evidence-based intervention (e.g. mode of delivery); practice setting
12
13 6 (e.g. information systems, training and staffing); and ecological systems (e.g. policies). To
14
15 7 determine the changes that had occurred in each of these areas since the initial trial,
16
17 8 consultations were undertaken with clinical representatives, and audits of antenatal schedules,
18
19 9 training records, staffing rosters, information systems, and resource and policy databases were
20
21 10 conducted.
22
23
24
25

26 11
27
28 12 Although it was found that there had been a marked increase in antenatal appointments
29
30 13 delivered via telehealth in response to the COVID-19 pandemic, telehealth care delivery
31
32 14 guidelines included alcohol care being delivered irrespective of appointment mode. An
33
34 15 assessment of systems and resources available to support care provision indicated that the
35
36 16 majority of strategies implemented in the initial trial were still fully or partially available. An
37
38 17 assessment of workforce turnover indicated that almost half of the current antenatal care
39
40 18 workforce was not employed at the time of the initial trial and almost half of these new staff
41
42 19 had not completed any of the training made available through the initial trial strategy. In
43
44 20 addition, no formal process that defined the roles and responsibilities of specific groups or staff
45
46 21 in ensuring the ongoing availability and use of supporting systems and resources, nor a formal
47
48 22 process for identifying when adaptations to the model of care and implementation strategies may
49
50 23 be required to address changes in circumstances. To address these factors, three strategies were
51
52 24 selected based on the sustainability literature and in consultation with experts in the field:
53
54
55
56
57
58
59
60

1
2
3 1 develop a formal implementation blueprint; purposely re-examine the implementation; and
4
5 2 conduct ongoing training⁵⁵ (see Additional File 3 for development of strategies).
6
7
8 3
9

10 4 **(Insert Figure 3 here)**
11
12 5
13
14 6
15

16 7 **(Insert Figure 4 here)**
17
18 8
19

20 9 ***Implementation delivery timeline***

21
22
23 10 The implementation support package will be delivered in each of the sectors sequentially for a
24
25 11 period of three months (see Figure 1). Strategies aimed at increasing the proportion of women
26
27 12 who receive antenatal care addressing alcohol consumption will be delivered in the first two
28
29 13 months of the implementation. Strategies aimed at sustaining the rate of care will be developed,
30
31 14 agreed to, and implemented in the third month. Given the focus on embedding sustainability,
32
33 15 the implementation support package has the potential to continue supporting care provision
34
35 16 following the three-month implementation.
36
37
38
39 17

40 18 **Control and contamination**

41 19 ***Usual Care***

42
43
44 20 In the pre-implementation data collection phase for each of the three sectors, usual antenatal
45
46 21 care for addressing alcohol consumption during pregnancy will be provided. Strategies
47
48 22 available to support care provision include: national and local clinical practice guidelines;
49
50 23 electronic medical record prompts; online education module; and performance data entered
51
52 24 into the health service's monitoring system quarterly. Care provision is likely to vary by
53
54 25 maternity service and clinician.
55
56
57
58
59
60 26

1 **Potential for contamination**

2 As the research team will control implementation delivery, the implementation support
3 package will not be accessible to maternity services during the pre-implementation (control)
4 phase.

5 **Patient and public involvement**

6 Pregnant women's acceptability of the model of care was considered in the development of the
7 evidence-based intervention for this trial. Antenatal care provider's feedback on the initial
8 implementation support package and new consultations with clinical representatives informed
9 the iterative development of this trial's support package. Consultations with Aboriginal health
10 staff were undertaken to embed cultural appropriateness for Aboriginal women across all
11 components of the trial. A Cultural Review Group containing only Aboriginal members,
12 including health service and community representatives, will review all dissemination
13 products.

14 **Measures**

15 **Primary trial outcomes**

16 The proportion of all pregnant women who report:

- 17 1. being asked about alcohol consumption at subsequent antenatal visits;
- 18 2. receiving complete care (advice and referral) relative to level of alcohol risk at
19 subsequent antenatal visits;
- 20 3. receiving complete care (advice and referral) relative to level of alcohol risk at the
21 initial antenatal visit.

22 **Process measures**

1
2
3 1 Fidelity, penetration/reach and acceptability will be assessed in accordance with the
4
5 2 implementation evaluation framework specified by Proctor et al.⁵⁷ Measures to assess
6
7 3 penetration/reach will include the proportion of eligible staff who were exposed to each of the
8
9 4 strategies. Acceptability of the strategies will be measured from the perspective of maternity
10
11 5 staff. Sustainment at the provider and inner-context levels will be measured from the
12
13 6 perspective of maternity staff using the three-item Provider REport of Sustainment Scale
14
15 7 (PRESS).⁵⁸ Changes occurring at the outer contextual level (e.g. social, political and economic
16
17 8 factors) that may influence practices will be monitored and reported.
18
19
20
21
22
23

24 10 ***Within-trial economic analyses***

25
26 11 A trial-based cost-effectiveness analysis (CEA) will calculate the incremental cost per unit
27
28 12 change in the primary trial outcomes and cost-consequence analysis (CCA) will disaggregate
29
30 13 results by sector. To assess the affordability of sustaining care over time within the resource
31
32 14 and budget constraints of the health service, a Budget Impact Analysis (BIA) will also be
33
34 15 conducted. All analyses will be conducted and reported in accordance with the Consolidated
35
36 16 Health Economic Evaluation Reporting Standards (CHEERS) publication guidelines and good
37
38 17 reporting practices guidelines.⁵⁹
39
40
41
42
43
44

45 19 **Data collection procedures**

46 20 ***Primary outcome measures***

47
48
49 21 Telephone contact will be attempted with sampled women up to 10 times over a two-week
50
51 22 period in order to elicit consent and completion of the survey. Women who decline
52
53 23 participation in the telephone survey will be offered the online survey. Aboriginal women
54
55 24 and/or women attending or enrolled to attend AMIHS will be offered the choice of telephone
56
57 25 or online mode at first contact. The telephone survey will be computer assisted and be
58
59
60

1 conducted by trained female interviewers. The questions and response options will be identical
2 in the telephone and online surveys. All data collected will be recorded in the online Research
3 Electronic Data Capture (REDCap).^{60 61}

4 5 ***Process measures***

6 Process measures will be collected through surveys with maternity staff and project
7 management logs. Surveys of maternity service staff will be conducted pre-implementation
8 (sustainment only) and post-implementation in each sector (penetration/reach, acceptability
9 and sustainment). Eligible staff will be sent a link to an online survey via email as well as given
10 the option to complete the survey on tablet computers or pen and paper during regular clinic
11 meetings. Additional process data will be collected by project staff during the implementation
12 period and recorded in project management logs.

13 14 ***Costs***

15 Resource use associated with the implementation support package will be prospectively
16 identified, measured and valued using a cost capture template to be developed in REDCap.^{60 61}
17 Implementation resources are expected to include labour and materials to support maternity
18 service staff. Costs associated with implementation will be recorded separately from those used
19 for sustainability.

20 21 **Sample size and power calculations**

22 Assuming that 225 women will complete a survey per month (approximately 150 for
23 subsequent antenatal visit time points and 75 for the initial antenatal visit time point), we will
24 have 80% power to detect an absolute increase of approximately (i) 15% in being asked about
25 alcohol consumption at subsequent antenatal visits (baseline prevalence of 42%); (ii) 13% in

1
2
3 1 complete care at subsequent antenatal visits (baseline prevalence of 23%); and (iii) 21% in
4
5 2 complete care at initial antenatal visits (baseline prevalence of 45%). This is assuming an ICC
6
7
8 3 of 0.01 and an alpha level of 1.67% (Bonferroni adjusted for the three primary outcomes).
9
10 4

11 5 **Statistical Analyses**

12
13
14 6 To address the first aim, pre-post differences in the proportion of women reporting receipt of
15
16 7 care for each of the three primary outcomes will be compared using generalised linear models
17
18 8 with a binomial distribution and logit link function. These models will compare the odds of
19
20 9 receiving care at post-implementation versus pre-implementation. Each model will contain a
21
22 10 term for period (pre or post implementation), sector (one, two, three), antenatal visit for the
23
24 11 outcomes on subsequent antenatal visits (28 weeks gestation, 36 weeks gestation) and time (in
25
26 12 months). An alpha level of 1.67% will be used to determine statistical significance. The odds
27
28 13 ratio and 95% confidence limit from the term for period will be presented as the intervention
29
30 14 effect.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

16 For the second aim, segmented regression within an interrupted time-series framework will be
17 used to assess women's receipt of care over time, and whether this improves and sustains
18 following the delivery of the implementation support package. These analyses will be on the
19 same three primary outcomes assessed in the pre-post difference analyses and will be
20 conducted separately for each of the three sectors. Replication of findings across the three
21 sectors will provide greater confidence in the intervention effect.⁶² Three segments will be
22 specified in each segmented regression, one for each of the study phases (i.e. pre-
23 implementation, implementation and post-implementation). The rate of change in the receipt
24 of care will be estimated for each of the three segments.

1
2
3 1 Exploratory secondary analyses will also be conducted to examine trial outcomes relative to
4
5 2 initial trial findings, including a comparison of the proportion of pregnant women receiving
6
7 3 guideline recommended care and rate of change per month of implementation support.
8
9 4

12 5 **Research trial governance**

14 6 The conduct of the trial will be overseen by an advisory group consisting of researchers,
15
16 7 practitioners and clinical experts with expertise related to alcohol consumption during
17
18 8 pregnancy, clinical practice change, sustainability, maternity services, Aboriginal health and
19
20 9 health economics. A project team consisting of research staff and a project dedicated CME will
21
22 10 operationalise all components of the trial according to study protocol.
23
24
25
26
27
28

29 12 **Aboriginal cultural governance**

30 13 Cultural governance will be embedded across the trial to be inclusive of Aboriginal people's
31
32 14 perspective. Aboriginal cultural task groups that are led by an Aboriginal project team member
33
34 15 will provide guidance on the delivery of the implementation support package. A Cultural
35
36 16 Review Group containing only Aboriginal members will review all dissemination products.
37
38
39
40
41

42 18 **Trial status**

43
44 19 Recruitment of Sector One will commence April 2022 and recruitment of the last Sector will
45
46 20 be completed in December 2022. Data collection will be completed by December 2023 and
47
48 21 data analysis will commence January 2024.
49
50
51
52

53 23 **ETHICS AND DISSEMINATION**

54 24 Ethical approval was obtained through the Hunter New England Human Research Ethics
55
56 25 Committee (16/11/16/4.07, 16/10/19/5.15); the University of Newcastle Human Research
57
58
59
60

1
2
3 1 Ethics Committee (H-2017-0032, H-2016-0422) and the Aboriginal Health and Medical
4
5 2 Research Council (1236/16). Any modifications to the protocol will be submitted to the
6
7 3 abovementioned ethics committees for approval prior to implementation. There are no pre-
8
9 4 determined criteria for trial discontinuation. Any unforeseen adverse events will be reported to
10
11 5 the Hunter New England Human Research Ethics Committee (primary approval committee).
12
13 6 The trial registry will be updated with any protocol modifications and any deviations from the
14
15 7 original protocol will be reported.
16
17
18
19
20
21

22 9 Participation in the women and staff surveys will be voluntary. Potential participants will
23
24 10 receive information about the study prior to providing verbal informed consent for surveys
25
26 11 conducted via phone or written consent for surveys completed via online/pen paper modes.
27
28 12 Women will have the opportunity to decline participation at any point, including after receiving
29
30 13 the study information flyer or participant letter; at the time of the telephone call or text message;
31
32 14 or partway through survey completion. Staff will also have the opportunity to decline
33
34 15 participation at any point. A data management protocol that was developed and approved by
35
36 16 the advisory group for the initial trial will be used in this trial. All data will be stored securely
37
38 17 as per the requirements of the approving ethics committees and confidential identifying
39
40 18 participant information will not be linked to survey responses. Data will only be accessible to
41
42 19 the project team.
43
44
45
46
47
48

49 21 Trial findings will be disseminated to health service decision makers to inform the feasibility
50
51 22 of conducting additional cycles to further improve antenatal care addressing alcohol
52
53 23 consumption. Findings will also inform the use of iterative improvement approaches for other
54
55 24 antenatal care guidelines in maternity services that have low adherence. Trial findings will be
56
57 25 disseminated to key stakeholder groups, including clinical representatives and Aboriginal
58
59
60

1 partners and community organisations. Lastly, outcomes will be disseminated through peer-
2 reviewed publications and at national and international conferences.

3
4
5
6
7
8
9
10
11 **Author contributions:** ED, MK, NN, AH and JW led the overall development of the research
12 protocol and ED led the development of the manuscript. JW, LW, MK and ED contributed to
13 the development of the rationale and background for the protocol. ED, LW, MK, NN, AH and
14 TM contributed to the development of the implementation support package. BT facilitated the
15 provision of cultural advice and establishment of cultural governance structures. IS contributed
16 clinical expertise relevant to the maternity services setting. EJE, AD and TWT contributed
17 clinical expertise relevant to alcohol consumption in pregnancy. ED and MK contributed to the
18 development of data collection methods generally and PR and OW contributed to the
19 development of data collection methods specific to the cost and cost effectiveness measures.
20 AH and JA provided overall guidance for the study design and data analysis. All authors read
21 and approved the final manuscript.

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39 **Funding:** This research received no specific grant from any funding agency in the public,
40 commercial or not-for-profit sectors.

41
42
43
44
45
46 **Competing interests:** None declared.

1 REFERENCES

1. Steane SE, Young SL, Clifton VL, et al. Prenatal alcohol consumption and placental outcomes: a systematic review and meta-analysis of clinical studies. *American Journal of Obstetrics & Gynecology* 2021;26:26. doi: <https://dx.doi.org/10.1016/j.ajog.2021.06.078>
2. Sundermann AC, Zhao S, Young CL, et al. Alcohol Use in Pregnancy and Miscarriage: A Systematic Review and Meta-Analysis. *Alcoholism: Clinical & Experimental Research* 2019;43(8):1606-16. doi: <https://dx.doi.org/10.1111/acer.14124>
3. Patra J, Bakker R, Irving H, et al. Dose-response relationship between alcohol consumption before and during pregnancy and the risks of low birthweight, preterm birth and small for gestational age (SGA)-a systematic review and meta-analyses. *BJOG: An International Journal of Obstetrics & Gynaecology* 2011;118(12):1411-21.
4. Henderson J, Gray R, Brocklehurst P. Systematic review of effects of low-moderate prenatal alcohol exposure on pregnancy outcome. *BJOG : an international journal of obstetrics and gynaecology* 2007;114(3):243-52. doi: 10.1111/j.1471-0528.2006.01163.x
5. Flak AL, Su S, Bertrand J, et al. The association of mild, moderate, and binge prenatal alcohol exposure and child neuropsychological outcomes: a meta-analysis. *Alcohol Clin Exp Res* 2014;38(1):214-26. doi: <http://dx.doi.org/10.1111/acer.12214>
6. Lucas BR, Latimer J, Pinto RZ, et al. Gross motor deficits in children prenatally exposed to alcohol: a meta-analysis. *Pediatrics* 2014;134(1):e192-209. doi: <https://dx.doi.org/10.1542/peds.2013-3733>
7. National Health and Medical Research Council. Australian Guidelines to Reduce Health Risks from Drinking Alcohol. Canberra: Commonwealth of Australia, 2020.
8. Popova S, Lange S, Probst C, et al. Estimation of national, regional, and global prevalence of alcohol use during pregnancy and fetal alcohol syndrome: a systematic review and meta-analysis. *The Lancet Global Health* 2017;5(3):e290-e99. doi: [https://doi.org/10.1016/S2214-109X\(17\)30021-9](https://doi.org/10.1016/S2214-109X(17)30021-9)
9. Ujhelyi Gomez K, Goodwin L, Jackson L, et al. Are psychosocial interventions effective in reducing alcohol consumption during pregnancy and motherhood? A systematic review and meta-analysis. *Addiction* 2021;116(7):1638-63. doi: <https://dx.doi.org/10.1111/add.15296>
10. World Health Organisation. Guidelines for the identification and management of substance use and substance use disorders in pregnancy. Geneva: WHO 2014.
11. Department of Health. Clinical Practice Guidelines: Pregnancy Care - 2019 Edition. Canberra: Australian Government Department of Health, 2019.

12. Australian Government Department of Health. Improving Maternity Services in Australia. The Report of the Maternity Services Review. Canberra: Department of Health, 2009.
13. NHS Digital. NHS Maternity Statistics, England 2020-2021. NHS Digital, 2021.
14. Wangberg SC. Norwegian midwives' use of screening for and brief interventions on alcohol use in pregnancy. *Sexual & Reproductive Healthcare* 2015;6(3):186-90. doi: 10.1016/j.srhc.2015.03.001
15. Kesmodel U, Schiøler Kesmodel P. Drinking during pregnancy: attitudes and knowledge among pregnant Danish women, 1998. *Alcoholism: Clinical and Experimental Research* 2002;26(10):1553-60. doi: 10.1111/j.1530-0277.2002.tb02455.x
16. Doherty E, Wiggers J, Wolfenden L, et al. Antenatal care for alcohol consumption during pregnancy: pregnant women's reported receipt of care and associated characteristics. *BMC Pregnancy & Childbirth* 2019;19(1):299.
17. Kesmodel US, Kesmodel PS. Alcohol in pregnancy: attitudes, knowledge, and information practice among midwives in Denmark 2000 to 2009. *Alcohol Clin Exp Res* 2011;35(12):2226-30.
18. Waller A, Bryant J, Cameron E, et al. Women's perceptions of antenatal care: are we following guideline recommended care? *BMC Pregnancy and Childbirth* 2016;16(1):191. doi: 10.1186/s12884-016-0984-y
19. Bazzo S, Battistella G, Riscica P, et al. Evaluation of a Multilevel and Integrated Program to Raise Awareness of the Harmful Effects of Prenatal Alcohol Exposure in a Local Community. *Alcohol Alcohol* 2015;50(6):708-15. doi: <https://dx.doi.org/10.1093/alcalc/aggv051>
20. Doherty E, Kingsland M, Elliott EJ, et al. Practice change intervention to improve antenatal care addressing alcohol consumption during pregnancy: a randomised stepped-wedge controlled trial. *BMC Pregnancy and Childbirth* 2022;22:345.
21. Flodgren G, Parmelli E, Doumit G, et al. Local opinion leaders: effects on professional practice and health care outcomes. *Cochrane Syst Rev* 2011;8
22. Rotter T, Kinsman L, James EL, et al. Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. *Cochrane Syst Rev* 2010(3) doi: 10.1002/14651858.CD006632.pub2
23. Shojanian et.al. The effects of on-screen, point of care computer reminders on processes and outcomes of care. *Cochrane Syst Rev* 2014(3: CD001096) doi: doi:10.1002/14651858.CD001096.pub2.

- 1 24. Woo K, Milworm G, Dowding D. Characteristics of Quality Improvement Champions in
2 Nursing Homes: A Systematic Review With Implications for Evidence-Based Practice.
3 *Worldviews on evidence-based nursing* 2017;14(6):440-46. doi: 10.1111/wvn.12262
- 4 25. Welsh SM, Sherriff A, Flodgren G. The champion for improved delivery of care to older
5 people in long-term care settings: effects on professional practice, quality of care and resident
6 outcomes. *Cochrane Syst Rev* 2015(11) doi: 10.1002/14651858.CD011956
- 7 26. Reeves S, Perrier L, Goldman J, et al. Interprofessional education: effects on professional
8 prac-tice and healthcare outcomes (update). *Cochrane Syst Rev* 2013;Issue 3:Art. No.:
9 CD002213.
- 10 27. Forsetlund L, Bjorndal A, Rashidian A, et al. Continuing education meetings and
11 workshops: effects on professional practice and health care outcomes. *Cochrane Syst Rev*
12 2009(2).
- 13 28. Chaillet N, Dube E, Dugas M, et al. Evidence-based strategies for implementing guidelines
14 in obstetrics: a systematic review. *Obstet Gynecol* 2006;108(5):1234-45. doi:
15 10.1097/01.AOG.0000236434.74160.8b
- 16 29. Ivers N, Jamtvedt G, Flottorp S. Audit and feedback: effects on professional practice and
17 healthcare outcomes. *Cochrane Syst Rev* 2012;Issue 6:Art. No.: CD000259.
- 18 30. O'Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: effects on
19 professional practice and health care outcomes. *Cochrane Syst Rev* 2007;4
- 20 31. McCrabb S, Mooney K, Elton B, et al. How to optimise public health interventions: a
21 scoping review of guidance from optimisation process frameworks. *BMC Public Health*
22 2020;20(1):1849. doi: <https://dx.doi.org/10.1186/s12889-020-09950-5>
- 23 32. Satcher D, Higginbotham EJ. The public health approach to eliminating disparities in
24 health. *American Journal of Public Health* 2008;98(3):400-3. doi:
25 <https://dx.doi.org/10.2105/AJPH.2007.123919>
- 26 33. O'Donnell B, Gupta V. Continuous Quality Improvement. *StatPearls Publishing*
27 2020;01:01.
- 28 34. Lynn J, Baily MA, Bottrell M, et al. The ethics of using quality improvement methods in
29 health care. *Annals of Internal Medicine* 2007;146(9):666-73.
- 30 35. Spencer E, Swanson T, Hueston WJ, et al. Tools to improve documentation of smoking
31 status. Continuous quality improvement and electronic medical records. *Archives of Family*
32 *Medicine* 1999;8(1):18-22.
- 33 36. Yapa HM, De Neve JW, Chetty T, et al. The impact of continuous quality improvement on
34 coverage of antenatal HIV care tests in rural South Africa: Results of a stepped-wedge cluster-

- 1
2
3 1 randomised controlled implementation trial. *PLoS Medicine / Public Library of Science*
4 2020;17(10):e1003150. doi: <https://dx.doi.org/10.1371/journal.pmed.1003150>
- 5 2
6 37. Gibson-Helm ME, Rumbold AR, Teede HJ, et al. Improving the provision of pregnancy
7 4 care for Aboriginal and Torres Strait Islander women: a continuous quality improvement
8 5 initiative. *BMC Pregnancy & Childbirth* 2016;16:118. doi: [https://dx.doi.org/10.1186/s12884-](https://dx.doi.org/10.1186/s12884-016-0892-1)
9 6 [016-0892-1](https://dx.doi.org/10.1186/s12884-016-0892-1)
- 10 7
11 38. Ament SM, de Groot JJ, Maessen JM, et al. Sustainability of professionals' adherence to
12 8 clinical practice guidelines in medical care: a systematic review. *BMJ Open*
13 9 2015;5(12):e008073. doi: <https://dx.doi.org/10.1136/bmjopen-2015-008073>
- 14 10
15 39. Cowie J, Nicoll A, Dimova ED, et al. The barriers and facilitators influencing the
16 11 sustainability of hospital-based interventions: a systematic review. *BMC Health Services*
17 12 *Research* 2020;20(1):588. doi: <https://dx.doi.org/10.1186/s12913-020-05434-9>
- 18 13
19 40. Hailemariam M, Bustos T, Montgomery B, et al. Evidence-based intervention sustainability
20 14 strategies: a systematic review. *Implementation Science* 2019;14(1):57. doi:
21 15 <https://dx.doi.org/10.1186/s13012-019-0910-6>
- 22 16
23 41. Nahimana E, Magge H, Bizimana F, et al. Sustainability Assessment of a District-Wide
24 17 Quality Improvement on Newborn Care Program in Rural Rwanda: A Mixed-Method Study.
25 18 *Annals of Global Health* 2021;87(1):40. doi: <https://dx.doi.org/10.5334/aogh.3205>
- 26 19
27 42. Ahluwalia IB, Robinson D, Vallely L, et al. Sustainability of community-capacity to
28 20 promote safer motherhood in northwestern Tanzania: what remains? *Global Health Promotion*
29 21 2010;17(1):39-49. doi: <https://dx.doi.org/10.1177/1757975909356627>
- 30 22
31 43. Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice
32 23 and healthcare outcomes. *Cochrane Syst Rev* 2012(6) doi: 10.1002/14651858.CD000259.pub3
- 33 24
34 44. Scott C, Andersen CT, Valdez N, et al. No global consensus: a cross-sectional survey of
35 25 maternal weight policies. *BMC Pregnancy Childbirth* 2014;14:167. doi: 10.1186/1471-2393-
36 26 14-167
- 37 27
38 45. New South Wales Ministry of Health, Centre for Epidemiology and Evidence. New South
39 28 Wales Mothers and Babies 2019 Report. Sydney: NSW Ministry of Health, 2021.
- 40 29
41 46. Stade BC, Bailey C, Dzendoletas D, et al. Psychological and/or educational interventions
42 30 for reducing alcohol consumption in pregnant women and women planning pregnancy.
43 31 *Cochrane syst rev* 2009(2):CD004228-CD28. doi: 10.1002/14651858.CD004228.pub2
- 44 32
45 47. Babor TF, Del Boca F, Bray JW. Screening, Brief Intervention and Referral to Treatment:
46 33 implications of SAMHSA's SBIRT initiative for substance abuse policy and practice.
47 34 *Addiction* 2017;112 Suppl 2:110-17. doi: <https://dx.doi.org/10.1111/add.13675>

- 1
2
3 1 48. Babor T F H-BJC, Saunders J B, Monteiro M G. AUDIT. The alcohol use disorders
4 2 identification test: Guidelines for use in primary care. World Health Organisation: Geneva,
5 3 2001.
6
7
8 4 49. New South Wales Health. Get Healthy in Pregnancy [Available from:
9 5 <https://www.gethealthynsw.com.au/program/get-healthy-in-pregnancy/> Date accessed:
10 6 22/06/2018.
11
12
13 7 50. Wolfenden L, Foy R, Pesseau J, et al. Designing and undertaking randomised
14 8 implementation trials: guide for researchers. *BMJ* 2021;372:m3721. doi:
15 9 <https://dx.doi.org/10.1136/bmj.m3721>
16
17
18 10 51. Atkins L, Francis J, Islam R, et al. A guide to using the Theoretical Domains Framework
19 11 of behaviour change to investigate implementation problems. *Implementation Science*
20 12 2017;12(1):77. doi: 10.1186/s13012-017-0605-9
21
22
23 13 52. French SD, Green SE, O'Connor DA, et al. Developing theory-informed behaviour change
24 14 interventions to implement evidence into practice: a systematic approach using the Theoretical
25 15 Domains Framework. *Implementation Science* 2012;7(1):1-8. doi: 10.1186/1748-5908-7-38
26
27
28 16 53. Flynn TN. Valuing citizen and patient preferences in health: recent developments in three
29 17 types of best-worst scaling. *Expert Rev Pharmacoecon Outcomes Res* 2010;10(3):259-67. doi:
30 18 10.1586/erp.10.29
31
32
33 19 54. Michie S, Johnston M, Francis J, et al. From Theory to Intervention: Mapping Theoretically
34 20 Derived Behavioural Determinants to Behaviour Change Techniques. *Applied Psychology*
35 21 2008;57(4):660-80. doi: 10.1111/j.1464-0597.2008.00341.x
36
37
38 22 55. Powell BJ, Waltz TJ, Chinman MJ, et al. A refined compilation of implementation
39 23 strategies: results from the Expert Recommendations for Implementing Change (ERIC)
40 24 project. *Implementation Science* 2015;10:21.
41
42
43 25 56. Chambers DA, Glasgow RE, Stange KC. The dynamic sustainability framework:
44 26 addressing the paradox of sustainment amid ongoing change. *Implementation Science*
45 27 2013;8:117. doi: <https://dx.doi.org/10.1186/1748-5908-8-117>
46
47
48 28 57. Proctor E, Silmere H, Raghavan R, et al. Outcomes for Implementation Research:
49 29 Conceptual Distinctions, Measurement Challenges, and Research Agenda. *Administration and*
50 30 *Policy in Mental Health and Mental Health Services Research* 2011;38(2):65-76. doi:
51 31 10.1007/s10488-010-0319-7
52
53
54 32 58. Moullin JC, Sklar M, Ehrhart MG, et al. Provider REport of Sustainment Scale (PRESS):
55 33 development and validation of a brief measure of inner context sustainment. *Implementation*
56 34 *Science* 2021;16(1):86. doi: <https://dx.doi.org/10.1186/s13012-021-01152-w>

- 1
2
3 1 59. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation
4 Reporting Standards (CHEERS) statement. *BMJ: British Medical Journal* 2013;346:1049-55.
5 2
6 3 doi: 10.1136/bmj.f1049
7
8 4 60. Harris PA TR, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture
9 (REDCap) - A metadata-driven methodology and workflow process for providing translational
10 5
11 6 research informatics support. *Journal of Biomedical Informatics* 2009;42(2):377-81.
12
13 7 61. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international
14 8
15 9 community of software platform partners. *Journal of biomedical informatics* 2019;95:103208.
16
17 10 62. Hawkins NG, Sanson-Fisher RW, Shakeshaft A, et al. The multiple baseline design for
18 11
19 12 evaluating population-based research. *American Journal of Preventive Medicine*
20 13
21 14 2007;33(2):162-8.
22
23 15
24 16
25 17
26 18
27 19
28 20
29 21
30 22
31 23
32 24
33 25
34 26
35 27
36 28
37 29
38 30
39 31
40 32
41 33
42 34
43 35
44 36
45 37
46 38
47 39
48 40
49 41
50 42
51 43
52 44
53 45
54 46
55 47
56 48
57 49
58 50
59 51
60 52

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **FIGURE LEGENDS**

2 **Figure 1.** Data collection and study design

3

4 **Figure 2.** Evidence-based model of antenatal care recommended for provision at the initial and
5 subsequent antenatal appointments

6

7 **Figure 3.** Implementation support packages used in initial and current trial

8


9 **Figure 4.** Logic model

For peer review only

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 |
|-----------------|--|---|---|---|---|---|----------------|---|---|---------------------|----|----|---------------------|----|----|---------------------|----|----|----|----|----|----|----|----|----|----|----|
| | Continuous data collection via women's surveys | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Sector 1 | Pre-implementation | | | | | | Implementation | | | Post-implementation | | | | | | | | | | | | | | | | | |
| Sector 2 | Pre-implementation | | | | | | | | | Implementation | | | Post-implementation | | | | | | | | | | | | | | |
| Sector 3 | Pre-implementation | | | | | | | | | | | | Implementation | | | Post-implementation | | | | | | | | | | | |
| | Additional 4 months of data to assess sustainment using a multiple baseline design | | | | | | | | | | | | | | | | | | | | | | | | | | |

Peer review only

Downloaded from <http://bmjopen.bmj.com/> on April 7, 2024 by guest. Protected by copyright.




| Initial trial | |
|---|--|
| Strategies to increase the proportion of pregnant women who receive recommended care (7 months) | |
| Leadership/ managerial supervision | |
| Meetings were held every 2 months with maternity service management to elicit operational support for the practice change. | |
| Local clinical practice guidelines | |
| A service level guideline and procedure document that outlined the model of care (with local referral options) was uploaded onto the health service's policy and guidelines directory and disseminated. | |
| Remind clinicians | |
| Modifications were made to the existing point-of-care electronic medical record system used by maternity services. Antenatal providers were also provided with written point of care prompts. | |
| Local opinion leaders/ champions | |
| A dedicated CME was appointed in each sector to provide individual, team and service level support in the uptake of the recommended model of care. | |
| Educational meetings and educational materials | |
| A 30-minute online training module and a series of face-to-face sessions (including a mix of didactic, interactive, case-study, group and one-on-one sessions) (~1 hour) were facilitated by the CME. | |
| Academic detailing, including audit and feedback | |
| Data that were collected from medical records and surveys with pregnant women who recently attended a service were fed back to antenatal providers by the CME and used to develop action plans. | |
| Monitoring and accountability for performance | |
| Performance measures for the model of care for addressing alcohol consumption during pregnancy were included in managers' existing monitoring and accountability frameworks. | |
| Strategies to sustain the rate of care over time | |
| No specific sustainability strategies | |




| Current trial | |
|--|--|
| Strategies to increase the proportion of pregnant women who receive recommended care (2 months) | |
| Remind clinicians | |
| Point of care prompts will be included on women's hard-copy medical records. Prompts will fit with each service's usual clinical workflow and include a place to record that action was taken in the appointment. Staff who are usually responsible for resource ordering and medical record file management will receive instructive support. | |
| Facilitation | |
| A CME will facilitate peer-to-peer interactive problem solving to identify behavioural cues for providing assessment and care within the clinical workflow of antenatal appointments. Action plans that document the identified cues will be developed and examples included in training for new antenatal providers. | |
| Conduct educational meetings | |
| A single 15-minute educational meeting will be conducted. A credible source (Paediatrician with expertise in FASD) will provide persuasive education on the harms of alcohol consumption to increase salience of the issue. A CME will then guide a discussion focusing on reframing the purpose of providing assessment and care for alcohol consumption in antenatal visits. | |
| Strategies to sustain the rate of care over time (1 month) | |
| Develop a formal implementation blueprint | |
| A formal implementation blueprint that plans for sustainability will be developed. The plan will define the roles and responsibilities of maternity services and the supporting agency in sustaining implementation and ensuring the ongoing availability, use and maintenance of the strategies. | |
| Purposely re-examine the implementation | |
| A process for reviewing the formal implementation blueprint will be developed. The first review will occur at six months and provide a mechanism to identify whether adaptations to the model of care and strategies are required. | |
| Conduct ongoing training | |
| Existing CME's will receive support and resources to schedule and conduct orientation training for new staff and top-up training for existing staff (schedule to be determined by, and fit with, usual service training). | |

Aim One: Increase the proportion of pregnant women who receive antenatal care addressing alcohol consumption



Aim Two: Sustain the rate of care over time.





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

| Section/item | Item No | Description | Section |
|-----------------------------------|---------|--|--------------|
| Administrative information | | | |
| Title | 1 | Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym | Title page |
| Trial registration | 2a | Trial identifier and registry name. If not yet registered, name of intended registry | Abstract |
| | 2b | All items from the World Health Organization Trial Registration Data Set | Abstract |
| Protocol version | 3 | Date and version identifier | N/A |
| Funding | 4 | Sources and types of financial, material, and other support | Funding |
| Roles and responsibilities | 5a | Names, affiliations, and roles of protocol contributors | Contributors |
| | 5b | Name and contact information for the trial sponsor | N/A |
| | 5c | Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities | N/A |

| | | | | |
|----|---|-----|---|--|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | 5d | Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 7.1a for data monitoring committee) | Research trial governance and Aboriginal cultural governance |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | Introduction | | | |
| 11 | | | | |
| 12 | Background and rationale | 6a | Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention | Introduction |
| 13 | | | | |
| 14 | | | | |
| 15 | | | | |
| 16 | | 6b | Explanation for choice of comparators | Study design and setting |
| 17 | | | | |
| 18 | Objectives | 7 | Specific objectives or hypotheses | Introduction |
| 19 | | | | |
| 20 | Trial design | 8 | Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority equivalence, noninferiority, exploratory) | Study design and setting |
| 21 | | | | |
| 22 | | | | |
| 23 | | | | |
| 24 | | | | |
| 25 | | | | |
| 26 | Methods: Participants, interventions, and outcomes | | | |
| 27 | | | | |
| 28 | Study setting | 9 | Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained | Study design and setting |
| 29 | | | | |
| 30 | | | | |
| 31 | | | | |
| 32 | Eligibility criteria | 10 | Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) | Participant eligibility and recruitment |
| 33 | | | | |
| 34 | | | | |
| 35 | | | | |
| 36 | | | | |
| 37 | Interventions | 11a | Interventions for each group with sufficient detail to allow replication, including how and when they will be administered | Model of care and implementation support package |
| 38 | | | | |
| 39 | | | | |
| 40 | | | | |
| 41 | | | | |
| 42 | | | | |
| 43 | | | | |
| 44 | | | | |
| 45 | | | | |
| 46 | | | | |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

| | | | |
|----------------------|-----|--|---|
| | 11b | Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) | N/A |
| | 11c | Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) | Data collection procedures |
| | 11d | Relevant concomitant care and interventions that are permitted or prohibited during the trial | N/A |
| Outcomes | 12 | Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended | Measures |
| Participant timeline | 13 | Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) | Study design and setting |
| Sample size | 14 | Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations | Sample size and power calculations |
| Recruitment | 15 | Strategies for achieving adequate participant enrolment to reach target sample size | Participant eligibility and recruitment |

Methods: Assignment of interventions (for controlled trials)

Allocation:

36/bmjopen-2022-068888 on 26 Jun 2022. Downloaded from <http://bmjopen.bmj.com/> by guest. Protected by copyright.

| | | | | |
|----|---|-----|--|---|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | Sequence generation | 16a | Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions | N/A |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | Allocation concealment | 16b | Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned | N/A |
| 11 | mechanism | | | |
| 12 | | | | |
| 13 | | | | |
| 14 | | | | |
| 15 | Implementation | 16c | Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions | Participant eligibility and recruitment |
| 16 | | | | |
| 17 | | | | |
| 18 | Blinding (masking) | 17a | Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how | Participant blinding |
| 19 | | | | |
| 20 | | | | |
| 21 | | 17b | If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial | Participant blinding |
| 22 | | | | |
| 23 | | | | |
| 24 | | | | |
| 25 | Methods: Data collection, management, and analysis | | | |
| 26 | Data collection methods | 18a | Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol | Data collection procedures |
| 27 | | | | |
| 28 | | | | |
| 29 | | | | |
| 30 | | | | |
| 31 | | | | |
| 32 | | | | |
| 33 | | | | |
| 34 | | | | |
| 35 | | 18b | Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols | N/A |
| 36 | | | | |
| 37 | | | | |
| 38 | | | | |
| 39 | | | | |
| 40 | | | | |
| 41 | | | | |
| 42 | | | | |
| 43 | | | | |
| 44 | | | | |
| 45 | | | | |
| 46 | | | | |

| | | | | |
|----|----------------------------|-----|---|----------------------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | Data management | 19 | Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol | Data collection procedures |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | Statistical methods | 20a | Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol | Statistical Analyses |
| 10 | | | | |
| 11 | | | | |
| 12 | | | | |
| 13 | | | | |
| 14 | | 20b | Methods for any additional analyses (eg, subgroup and adjusted analyses) | Statistical Analyses |
| 15 | | | | |
| 16 | | 20c | Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | Methods: Monitoring | | | |
| 21 | | | | |
| 22 | Data monitoring | 21a | Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed | Ethics and dissemination |
| 23 | | | | |
| 24 | | | | |
| 25 | | | | |
| 26 | | | | |
| 27 | | | | |
| 28 | | | | |
| 29 | | 21b | Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial | Ethics and dissemination |
| 30 | | | | |
| 31 | | | | |
| 32 | | | | |
| 33 | | | | |
| 34 | Harms | 22 | Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct | Ethics and dissemination |
| 35 | | | | |
| 36 | | | | |
| 37 | | | | |
| 38 | | | | |
| 39 | | | | |
| 40 | | | | |
| 41 | | | | |
| 42 | | | | |
| 43 | | | | |
| 44 | | | | |
| 45 | | | | |
| 46 | | | | |

36/bmjopen-2022-068001 on 26 July 2022. Downloaded from <http://bmjopen.bmj.com/> by guest. Protected by copyright.

36/bmjopen-2022-066886 on 26 July 2022. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.

| | | | | |
|----|---------------------------------|-----|---|--------------------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | Auditing | 23 | Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor | N/A |
| 5 | | | | |
| 6 | | | | |
| 7 | Ethics and dissemination | | | |
| 8 | | | | |
| 9 | Research ethics approval | 24 | Plans for seeking research ethics committee/institutional review board (REC/IRB) approval | Ethics and dissemination |
| 10 | | | | |
| 11 | | | | |
| 12 | Protocol amendments | 25 | Plans for communicating important protocol modifications (eg, change to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) | Ethics and dissemination |
| 13 | | | | |
| 14 | | | | |
| 15 | | | | |
| 16 | | | | |
| 17 | Consent or assent | 26a | Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) | Ethics and dissemination |
| 18 | | | | |
| 19 | | | | |
| 20 | | 26b | Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable | N/A |
| 21 | | | | |
| 22 | | | | |
| 23 | Confidentiality | 27 | How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial | Ethics and dissemination |
| 24 | | | | |
| 25 | | | | |
| 26 | | | | |
| 27 | | | | |
| 28 | Declaration of interests | 28 | Financial and other competing interests for principal investigators for the overall trial and each study site | Competing interests |
| 29 | | | | |
| 30 | | | | |
| 31 | Access to data | 29 | Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators | Ethics and dissemination |
| 32 | | | | |
| 33 | | | | |
| 34 | Ancillary and post-trial care | 30 | Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation | N/A |
| 35 | | | | |
| 36 | | | | |
| 37 | | | | |
| 38 | | | | |
| 39 | | | | |
| 40 | | | | |
| 41 | | | | |
| 42 | | | | |
| 43 | | | | |
| 44 | | | | |
| 45 | | | | |
| 46 | | | | |

| | | | |
|----------------------------|-----|---|--------------------------|
| Dissemination policy | 31a | Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions | Ethics and dissemination |
| | 31b | Authorship eligibility guidelines and any intended use of professional writers | Ethics and dissemination |
| | 31c | Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code | N/A |
| Appendices | | | |
| Informed consent materials | 32 | Model consent form and other related documentation given to participants and authorised surrogates | N/A |
| Biological specimens | 33 | Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable | N/A |

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

Additional File 2. Development of strategies to increase the proportion of pregnant women who receive assessment at subsequent antenatal visits and care at all antenatal visits.

| Priority barrier | COM-B (source of behaviour) & TDF domains | Intervention function | Behaviour Change Technique (BCT) | Mechanism of Action (MoA) | Implementation strategy [47] | Strategy description | Sustainability of technique |
|--|---|---|---|---|------------------------------|---|--|
| I forget to assess alcohol consumption at subsequent antenatal visits | COM-B: Physical opportunity | <ul style="list-style-type: none"> Environmental restructuring | <ul style="list-style-type: none"> Restructuring the physical environment Prompts, triggers, cues | <ul style="list-style-type: none"> Environmental context and resources Memory, attention and decision processes Behavioural cueing | Remind clinicians | <ul style="list-style-type: none"> Point of care prompts for assessment of alcohol consumption at subsequent antenatal visits and advice on the risks of alcohol consumption in pregnancy will be included on women's medical records. The placement of the prompts will fit with each service's usual clinical workflow. The prompts will include a place to record that action was taken in the visit. | Staff who are usually responsible for ordering resources and managing medical record files in each of the services will receive instruction in the ordering and placement of the prompts in the women's medical records. |
| I forget to explain the risks of alcohol consumption in pregnancy to all women | COM-B: Psychological capability | <ul style="list-style-type: none"> Enablement | <ul style="list-style-type: none"> Action planning | <ul style="list-style-type: none"> Behavioural cueing | Facilitation | <ul style="list-style-type: none"> A CME will facilitate a process of peer-to-peer interactive problem solving and support with antenatal providers to identify behavioural cues for providing assessment and care within antenatal visit clinical workflow. Action plans that document the identified cues in clinical workflow will be developed. | Examples of identified behavioural cues will be included in existing training and resources for new antenatal providers. |

| Priority barrier | COM-B (source of behaviour) & TDF domains | Intervention function | Behaviour Change Technique (BCT) | Mechanism of Action (MoA) | Implementation strategy [47] | Strategy description | Sustainability of technique |
|--|--|---|---|---|-------------------------------------|--|--|
| <p>I don't believe alcohol needs to be assessed at subsequent visits</p> <p>I don't believe the risks of alcohol consumption need to be explained to all women</p> | <p>COM-B: Reflective motivation</p> <p>TDF: Beliefs about consequences</p> | <ul style="list-style-type: none"> • Education • Persuasion | <ul style="list-style-type: none"> • Information about health consequences • Credible source • Framing/reframing | <ul style="list-style-type: none"> • Beliefs about consequences • Intention • Attitude towards the behaviour • Perceived susceptibility/vulnerability | <p>Conduct educational meetings</p> | <ul style="list-style-type: none"> • Information on the harms of alcohol consumption in pregnancy will be delivered by an expert in FASD. • A CME will guide a discussion with antenatal providers to reframe the purpose of providing assessment and care for alcohol consumption in multiple antenatal visits. | <p>Maternity services will be supported to incorporate this education into existing resources and schedules.</p> |

Additional File 3. Development of strategies to sustain the rate of care over time

| Factor potentially impacting sustainability | Sustainability strategy | Description |
|---|---|---|
| The roles and responsibilities of maternity services and support agencies in ensuring the ongoing availability and usage of the implementation strategies had not been formally defined | Develop a formal implementation blueprint | <ul style="list-style-type: none"> • A formal implementation blueprint that plans for sustainability will be developed and agreed to by maternity service leads in consultation with the supporting agency (Population Health Unit within the same Local Health District as the maternity services). • The plan will define the roles and responsibilities of maternity services in the continued provision of the model of care as part of routine practice. • The plan will define the roles and responsibilities of key maternity service groups/positions (maternity leadership, administrative staff, CME's) and the supporting agency in ensuring the ongoing availability, use and maintenance of the strategies implemented to support practice. |
| No process to review the fit of the model of care within current maternity service context and to audit the availability, usage and maintenance of the implementation strategies | Purposely re-examine the implementation | <ul style="list-style-type: none"> • A process for reviewing the formal implementation blueprint will be developed and agreed to by maternity service leads in consultation with the supporting agency. • The review will provide a mechanism to identify whether adaptations to the model of care and strategies supporting practice need to be made. • The first review will occur six months after the commencement of the intervention in each maternity service. |
| High staff turnover in maternity services | Conduct ongoing training | <ul style="list-style-type: none"> • Existing CME's in each of the services will receive support and resources to schedule and conduct orientation training for new staff and top-up training for existing staff. |